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Résumé 
L’objectif de ce projet était de développer une formulation liquisolide (LS) de 
clozapine ayant des propriétés de dissolution améliorées et évaluer sa stabilité et ainsi que sa 
robustesse à la modification d’excipients. Le propylène glycol (PG), la cellulose 
microcrystalline (MCC) et le glycolate d’amidon sodique (SSG) ont été utilisés 
respectivement en tant que véhicule liquide non volatile, agent de masse et agent désintégrant 
pour la préparation de comprimés LS. Le dioxyde de silicium colloïdal (CSD), le silicate de 
calcium (CS) et l'aluminométasilicate de magnésium (MAMS) ont été choisis comme agents 
d’enrobage sec. La caractérisation complète des mélanges et des comprimés a été effectuée. Le 
taux de libération des comprimés LS était statistiquement supérieur à celui des comprimés 
réguliers. La surface spécifique des matériaux d’enrobage avait un effet sur les propriétés 
d’écoulement des mélanges et la taille des particules des matériaux d’enrobage a eu un effet 
sur la vitesse de dissolution. Le ratio support/enrobage du mélange de poudres (valeur de R) 
était un paramètre important pour les systèmes LS et devait être plus grand que 20 afin 
d’obtenir une meilleure libération du médicament. La formulation choisie a démontré une 
stabilité pour une période d’au moins 12 mois. La technique LS s’est avéré une approche 
efficace pour le développement de comprimés de clozapine ayant des propriétés de dissolution 
améliorées.  
 
Les comprimés oro-dispersibles (ODT) sont une formulation innovante qui permettent 
de surmonter les problèmes de déglutition et de fournir un début d'action plus rapide. Dans 
l’optique d’améliorer les propriétés de dissolution, un essai a été effectué pour étudier la 
technique LS dans la formulation des ODT de clozapine. Le PG, la MCC, le CSD et la 
crospovidone (CP) ont été utilisés respectivement en tant que véhicule liquide non volatile, 
agent de masse, agent d’enrobage sec et agent superdésintégrant pour la préparation de 
comprimés oro-dispersibles liquisolides (OD-LST). Le mannitol a été choisi comme agent de 
masse et agent édulcorant. La saccharine de sodium a été utilisée comme agent édulcorant. La 
caractérisation complète des comprimés a été effectuée. Le taux de libération des OD-LSTs 
était statisquement supérieur comparativement aux comprimés ODTs. La formulation choisie a 
démontré une stabilité pour une période d’au moins 6 mois. Il a été conclu que des ODT de 
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clozapine peuvent être préparés avec succès en utilisant la technologie LS dans le but 
d’améliorer la désintégration et le taux de dissolution de la clozapine dans la cavité orale. 
 
Mots-clés : Liquisolide, clozapine, formulation, comprimé, oro-dispersible, excipients, 
superdésintegrant, dissolution, stabilité. 
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Abstract 
The objective of this research was to develop a liquisolid (LS) formulation of 
clozapine with improved dissolution properties and evaluate its robustness to excipient 
modifications as well as its stability. Propylene glycol (PG), microcrystalline cellulose (MCC) 
and sodium starch glycolate (SSG) were employed as non-volatile liquid vehicle, carrier 
material and disintegrant respectively for preparing LS compacts. Colloidal silicon dioxide 
(CSD), calcium silicate (CS) and magnesium aluminometasilicate (MAMS) were selected as 
coating materials. Complete characterisation of the blends and tablets was performed. The 
drug release rates of LS compacts were distinctly higher as compared to regular tablets. The 
specific surface areas of coating materials had an effect on the flow properties of the blends 
and the particle sizes of coating materials affected the dissolution rate. The carrier : coating 
ratio of the powder system (R value)  was an important parameter for LS systems and had to 
be larger than 20 to obtain enhanced drug release. The selected formulation demonstrated 
stability for a period of at least 12 months. The LS technique was an effective approach to 
prepare clozapine tablets with enhanced dissolution properties. 
 
Orally disintegrating tablets (ODT) constitute an innovative dosage form that 
overcomes the problems of swallowing and provides a quick onset of action. In view of 
enhancing dissolution properties an attempt has been made to study LS technique in 
formulation of ODT of clozapine. PG, MCC, CSD and crospovidone (CP) were employed as 
non-volatile liquid vehicle, carrier material, coating material and superdisintegrant 
respectively for preparing orally disintegrating liquisolid tablets (OD-LST). Mannitol was 
selected as a carrier material and sweetening agent. Sodium saccharin (SS) was employed as a 
sweetening agent. Complete characterisation of the tablets was performed. The drug release 
rates of OD-LSTs were distinctly higher as compared to regular ODTs. The selected 
formulation demonstrated stability for a period of at least 6 months. It was concluded that the 
ODT of clozapine can be successfully prepared using LS technology in order to improve 
disintegration and dissolution rate of clozapine in oral cavity.   
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Chapter one  
 
1 Introduction  
 
1.1 Liquisolid (LS) technology 
1.1.1 Overview 
Solubility is one of the important parameters to achieve desired concentration of drug 
in systemic circulation for pharmacological response to be shown
 
(Charman and Charman 
2003). Poorly water soluble drugs will be inherently released at a slow rate owing to their 
limited dissolution rate within the gastrointestinal tract (GIT) contents. One challenge for 
poorly water soluble drugs is to enhance the rate of dissolution (Darwish and El-Kamel 2001).  
 
Various techniques have been employed to formulate oral drug delivery system that 
would enhance the dissolution profile and in turn, the absorption efficiency of poorly water 
soluble drugs (Shinde 2007; Patel and Patel 2008): Solid dispersions (Kapsi and Ayres 2001; 
Shah, Amin et al. 2007; Rane, Mashru et al. 2007; Vanshiv, Rao et al. 2009), micronization 
(Li, Wang et al. 2007; Nighute and Bhise 2009), use of mesoporous silica carriers (Ahuja and 
Pathak 2009), ball milling technique (Sonoda, Horibe et al. 2008), use of complexing agents 
(El-Zein, Riad et al. 1998; Pravin and Nagarsenker 2004; Ghorab, Abdel-Salam et al. 2004; 
Gowrishankar, Ali et al. 2007), crystal engineering (Blagden, de Matas et al. 2007), 
solubilization by surfactants (Nazzal, Nutan et al. 2002; Patil and Paradkar 2006) and 
liquisolid (LS) technique developed by Spireas et al. (Spireas and Bolton 1999; Spireas 2002). 
These techniques take advantage of the increased dissolution rate resulting from the addition 
of a solubilizing agent, particle size reduction or the drug being in an already dissolved or 
amorphous state.  
 
LS technique has been identified as a promising technique to improve the dissolution 
rate of poorly water soluble drugs (Fahmy and Kassem 2008). When properly formulated, LS 
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powder blends possess acceptable flowability and compressibility properties. They are 
prepared by simple blending with selected powder excipients referred to as the carriers and the 
coating materials.  
 
This technique was successfully applied for low dose poorly water soluble drugs. Drug 
can be present in a completely or partially dissolved state in the LS formulation. The LS 
formulation can then facilitate the release of this drug by two mechanisms: (1) Already 
dissolved drug only need to diffuse out of the formulation and (2) the liquid component of the 
formulation act as a solubilizing aid to facilitate the wetting and dissolution of undissolved 
particles. Since dissolution of a non-polar drug is often the rate limiting step in gastrointestinal 
absorption, better bioavailability of an orally administered poorly water soluble drug is 
achieved when the drug is formulated using a LS system.  
  
1.1.2 Classification of LS systems 
The term LS systems refers to the powdered forms of liquid medications formulated by 
converting liquid lipophilic drugs or drug suspensions or solutions of water insoluble solid 
drugs in suitable non-volatile solvent systems, into dry, non-adherent, free flowing and readily 
compressible powder admixtures by blending with the selected carrier and coating materials 
(Figure 1.1). 
 
 
 
 
3 
 
 
 
 
 
 
Figure 1.1 Schematic representation of the structure of the liquisolid systems 
 
Based on the type of liquid medication encapsulated, LS systems may be classified into 
three subgroups: (1) Powdered drug solutions, (2) powdered drug suspensions and (3) 
powdered liquid drugs.  
 
Simultaneously, based on the formulation technique used, LS systems may be 
classified into two categories namely: (1) LS compacts and (2) LS microsystems.  
 
The term LS compacts refers to immediate or sustained release tablets or capsules 
prepared, combined with the inclusion of appropriate excipients required for tableting or 
encapsulation, such as lubricants and for rapid or sustained release action, such as 
disintegrants or binders, respectively. 
 
The term LS microsystems refers to capsules prepared by combining the drug with the 
carrier and the coating materials with inclusion of an additive in the liquid medication wherein 
the resulting unit size may be as much as five times that of LS compacts (Spireas and Bolton 
1999; Spireas 2002). 
Liquid drug, 
drug solution or 
drug suspension 
Carrier saturated with 
liquid (wet layer) 
Coating particles                    
(dry surface) 
4 
 
1.1.3 Excipients used for the preparation of LS systems 
1.1.3.1   Non-volatile solvents 
With the LS technology as described by Spireas, a liquid may be transformed into free 
flowing, readily compressible and apparently dry powder by simple blending with selected 
excipients such as the carriers and coating materials. The liquid portion, which can be a liquid 
drug, a drug suspension or a drug solution in suitable non-volatile solvents is incorporated into 
the porous carrier material. Inert, preferably water-miscible, not highly viscous, non-toxic 
organic solvents with high boiling point such as propylene glycol (PG), liquid polyethylene 
glycols (PEG), glycerine and polysorbates are best suitable as liquid vehicles (Kulkarni, 
Aloorkar et al. 2010). Once the carrier is saturated with liquid, a liquid layer is formed on the 
particle surface which is instantly adsorbed by the fine coating particles. Thus, an apparently 
dry, free flowing and compressible powder is obtained (Spireas 2002).  
 
Non-volatile solvents enhance the solubility of poorly water soluble drugs by 
formation of micelles and act as dispersants. For immediate release LS compacts, the selection 
of solvent is based on high drug solubility and for sustained release, solvents with least 
solubilizing capacity is selected. Since there are no specific non-volatile liquid vehicles used 
in the preparation of LS compacts, different non-aqueous solvents have been used as non-
volatile liquid vehicles in the preparation of immediate release and sustained release LS 
formulations with different drugs. So, selection of non-volatile solvent in LS technique is 
important to obtain immediate or sustained release formulation (Baby, Saroj et al. 2012).  
 
In various studies, the effect of different types of non-volatile liquid vehicles has been 
investigated. The results suggest that the selection of a liquid vehicle with a high solubilizing 
capacity for the drug and thus, an increased the fraction of molecularly dispersed drug (FM), 
leads to enhanced release profiles (Spireas and Sadu 1998; Nokhodchi, Javadzadeh et al. 2005; 
Javadzadeh, Siahi et al. 2007; Gubbi and Jarag 2009; Akinlade, Elkordy et al. 2010). That 
means that by the selection of a liquid vehicle with optimum solubilizing properties the 
amount of liquid and thus, the weight and size of the LS compacts can be reduced. However, 
in addition to the drug solubility in the liquid vehicle other physicochemical characteristics of 
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the liquid vehicles such as polarity, viscosity, molecular weight, chemical structure and 
lipophilicity may also have an effect on drug release (Spireas and Sadu 1998).  
 
 Propylene glycol (PG), an inert solvent miscible with water is a suitable liquid vehicle 
for LS systems. It is not highly viscous (dynamic viscosity: 58.1 cP at 20 °C) and has a high 
boiling point (188 °C). PG is used in a wide variety of pharmaceutical formulations and is 
generally regarded as a relatively non-toxic material (Handbook of Pharmaceutical Excipients 
2009; Baby, Saroj et al. 2012). 
 
PG was successfully used as non-volatile solvent in LS preparation of drugs such as 
bromhexine hydrochloride (Gubbi and Jarag 2009), famotidine (Fahmy and Kassem 2008), 
pioglitazone hydrochloride (Gandhi, Sawant et al. 2013), simvastatin (Burra, Kudikula et al. 
2011), to name a few.
 
 
1.1.3.2   Carrier materials 
In LS approach, the carrier material plays as a major role in obtaining the dry form of 
the powder from the liquid medication. Each carrier has its unique property. Selection of the 
carrier will depend upon its liquid holding capacity, the flowability of the powder and which 
carrier requires less compression force (Kavita, Raju et al. 2011).  
 
When the drug dissolved in liquid is incorporated into a carrier material, the liquid is 
initially absorbed in the interior of the particles. Once the carrier is saturated with liquid, a 
liquid layer is formed on the particle surface which is instantly adsorbed by the fine coating 
material particles. The coating material provides the conversion from a wet to a dry surface 
and gives the LS system desirable flow properties (Gavali, Pacharane et al. 2011).  
 
The particles of the carrier materials are compression enhancing, relatively large, 
preferably porous particles possessing sufficient absorption property which contributes in 
liquid absorption, e.g. various grades of microcrystalline cellulose (MCC) (Spireas 2002), 
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starch (Spireas 2002), lactose (Javadzadeh, Siahi et al. 2007), sorbitol (Javadzadeh, Siahi et al. 
2007), dibasic calcium phosphate (DCP) (Yadav and Yadav 2009) etc.  
 
 Microcrystalline cellulose (MCC) is a purified, partially depolymerized cellulose 
that occurs as a white, odorless, tasteless, crystalline powder composed of porous particles. It 
is commercially available in different particle sizes and moisture grades that have different 
properties and applications. The specific surface areas and particle sizes of carrier materials 
are important parameters for the optimization of LS systems. 
 
MCC is widely used in pharmaceuticals, primarily as a binder/diluent in oral tablet and 
capsule formulations where it is used in both wet granulation and direct compression 
processes.
 
In addition to its use as a binder/diluent, MCC has some lubricant
 
and disintegrant 
properties that make it useful in tableting (Handbook of Pharmaceutical Excipients 2009). 
 
MCC was successfully used as carrier material in LS preparation of drugs such as 
furosemide (Akinlade, Elkordy et al. 2010), griseofulvin (Hentzschel, Alnaief et al. 2011), 
hydrocortisone (Spireas, Sadu et al. 1998), irbesartan (Boghra, Patel et al. 2011), pioglitazone 
hydrochloride (Gandhi, Sawant et al. 2013), piroxicam (Javadzadeh, Siahi et al. 2005), 
rofecoxib (El-Say, Samy et al. 2010), tamoxifen citrate (Walunj, Sharma et al. 2012) to name a 
few. 
 
1.1.3.3   Coating materials 
The particles of the coating materials are flow enhancing, highly adsorptive particles, 
e.g. silica of various grades like medium surface fumed silica, colloidal silicon dioxide (CSD), 
synthetic amorphous silica, calcium silicate (CS), magnesium aluminometasilicate (MAMS). 
These particles contribute in covering the wet carrier particles and displaying a dry looking 
powder by adsorbing any excess liquid (Spireas and Bolton 1999; Spireas and Bolton 2000; 
Spireas 2002). The coating material is required to cover the surface and so maintain the 
powder flowability (Yadav and Yadav 2010).  
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Colloidal silicon dioxide (CSD), a submicroscopic fumed silica is a suitable coating 
material for LS systems. Its specific surface area is 100–400 m2/g depending on grade. The 
specific surface area of Aerosil
®
 200 is 200 ± 25 m2/g. Primary particle size is 7–16 nm. 
Aerosil
®
 forms loose agglomerates of 10–200 µm (Handbook of Pharmaceutical Excipients 
2009). 
 
CSD is widely used in pharmaceuticals, cosmetics and food products. Its small particle 
size and large specific surface area give it desirable flow characteristics that are exploited to 
improve the flow properties of dry powders
 
in a number of processes such as tableting
 
and 
capsule filling.  
 
CSD was successfully used as coating material in LS preparation of drugs such as 
carvedilol (Pardhi, Shivhare et al. 2010), hydrocortisone (Spireas, Sadu et al. 1998), irbesartan 
(Boghra, Patel et al. 2011), pioglitazone hydrochloride (Gandhi, Sawant et al. 2013), 
piroxicam (Javadzadeh, Siahi et al. 2005), rofecoxib (El-Say, Samy et al. 2010), tamoxifen 
citrate (Walunj, Sharma et al. 2012), valsartan (Lakshmi, Srinivas et al. 2011), to name a few. 
 
Calcium silicate (CS) has large micropores and excellent tabletability, also leads to a 
physical stabilization of amorphous drugs with enhanced drug release. CS possesses many 
intraparticle pores on its surface. Moreover, it has been shown that this silicate is also suitable 
for adsorption of liquid (Sharma, Sher et al. 2005). It can absorb up to 2.5 times its weight of 
liquids and still remain a free flowing powder (Handbook of Pharmaceutical Excipients 2009). 
CS is used as a filler aid for oral pharmaceuticals. It has also been used in pharmaceutical 
preparations as an antacid.  
 
 CS is used as coating material in LS preparation of some drugs. Repaglinide is widely 
used for the treatment of diabetes. It is a poorly water soluble drug which has poor absorption 
in the upper intestinal tract and has a very low bioavailability (Shams, Sayeed et al. 2011). The 
LS compacts of repaglinide were prepared using CS as a coating material (El-Houssieny, 
Wahman et al. 2010).   
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Tocopherol acetate (vitamin E acetate) is an oil soluble liquid drug. Hentzschel et al. 
investigated the suitability of various novel coating materials such as CS (Florite
®
), MAMS 
(Neusilin
® 
US2) for LS compacts of tocopherol acetate (Hentzschel, Sakmann et al. 2011). 
 
Neusilin
®
 US2, a synthetic amorphous form of MAMS which is prepared by spray 
drying and provides an extremely large specific surface area (300 m2/g) and good flow and 
tableting properties. The high porosity and large specific surface area of Neusilin
®
 allow a 
high liquid adsorption capacity (Hentzschel, Sakmann et al. 2011). This may be of interest 
especially for the preparation of LS compacts. Neusilin
®
 makes hard tablets at low 
compression forces compared to similar binders. Primary particle size of neutral grade of 
Neusilin
®
 US2 is 44-177 µm.  It is a multifunctional excipient that can be used in both direct 
compression and wet granulation of solid dosage forms. Neusilin
®
 is widely used for 
improvement of the quality of tablets, powders, granules and capsules. 
  
Neusilin
® 
was used as coating material in LS preparation of some drugs.                   
Cyclosporine-A is a fat soluble, hydrophobic polypeptide metabolite of fungus beauveria 
nivea (formerly tolypocladium inflatum gams). It is a hydrophobic cyclic peptide built from 
non-mammalian aminoacids with low oral bioavailability; which is one of first line 
immunosuppressive drugs used to prevent transplant rejection and to treat autoimmune 
diseases. The self-emulsifying cyclosporine-A tablets were prepared by the LS compaction 
technique using MAMS (Neusilin
®
 S1) as a coating material (Zhao, Zhou et al. 2011).  
 
Griseofulvin is an antifungal drug which has very low solubility in water. The LS 
compacts of griseofulvin were prepared using colloidal silica and MAMS (Neusilin
® 
US2)
 
as 
coating materials (Hentzschel, Alnaief et al. 2011). 
 
1.1.3.4   Disintegrants 
Disintegrants indirectly affect the dissolution parameter since the immediate next step 
is dissolution (Kavitha, Raju et al. 2011). To aid dissolution, tablet formulations generally 
require rapid disintegration, which can be facilitated by the addition of superdisintegrants.  
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Once a tablet disintegrates, the solubility properties of the drug, either alone or assisted 
by other formulation ingredients, determine the drug's subsequent dissolution rate and extent  
of release. The solubility properties of water-soluble drugs result in rapid and high-level drug 
release, but with poorly water soluble drugs, other ingredients in the formulation, including the 
disintegrant, play a key role in determining the drug dissolution characteristics exhibited by 
the finished formulation (Balasubramaniam and Bee 2009). Sodium starch glycolate (SSG), 
croscarmellose sodium (CCS), pregelatinized starch, crospovidone (CP) etc. are most 
commonly used disintegrants (Rajesh, Rajalakshmi et al. 2011). 
   
Sodium starch glycolate (SSG) is widely used in oral pharmaceuticals as a 
disintegrant in capsule and tablet formulations.
 
It is commonly used in tablets prepared by 
either direct compression or wet granulation processes.
 
The mechanism by which 
disintegration action takes place is rapid absorption of water and swell leading to an enormous 
increase in volume of granules which result in rapid and uniform disintegration. The higher 
dissolution rates observed with superdisintegrants may be due to rapid disintegration and fine 
dispersion of particles formed after disintegration (Kumar and Nirmala 2012). 
 
SSG is successfully used as disintegrant in LS preparation of drugs such as atorvastatin 
calcium (Gubbi and Jarag 2010), bromhexine hydrochloride (Gubbi and Jarag 2009), 
diazepam (Manogar, Hari et al. 2011), irbesartan (Boghra, Patel et al. 2011), pioglitazone 
hydrochloride (Gandhi, Sawant et al. 2013) etc.  
 
1.1.3.5   Drug candidates 
LS technique has been successfully employed to improve the dissolution rate of poorly 
water soluble or water insoluble drugs which belong to Biopharmaceutical Classification 
System (BCS) Class II or IV. Some of developed LS systems are listed in Table 1.1. These LS 
systems are the compacts based on the formulation technique used.  
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Table1.1 List of some of developed liquisolid systems to enhance dissolution rate 
Drug  Therapeutic class/ 
BCS class 
Liquid vehicle Carrier / Coating materials Reference 
Aceclofenac Nonsteroidal 
antiinflammatory drug 
(NSAID)/Class II 
PEG 400 MCC, DCP /  
Hydroxypropylmethyl 
cellulose (HPMC) 
Yadav, Nighute et al. 2009 
Amlodipine besylate Antihypertensive/            
Class II 
PG MCC / Silica Kaur, Bala et al. 2013 
Atorvastatin calcium Lipid lowering agent/ 
Class II 
PEG 400, PG MCC / Silica Gubbi and Jarag 2010 
Bromhexine HCl Mucolytic agent/               
Class II 
PEG 400, PG MCC / Silica Gubbi and Jarag 2009 
Candesartan cilexetil Antihypertensive/   
Class II 
Polysorbate 80 MCC / Silica Sayyad, Tulsankar et al. 2013 
Carbamazepine Antiepileptic/Class II PEG 200 MCC, Lactose / Silica Javadzadeh, Navimipour et al. 
2007 
Carbamazepine Antiepileptic/Class II PG MCC / Silica Tayel, Soliman et al. 2008 
Carvedilol Nonselective beta 
blocker/alpha 1 blocker/ 
Class II 
PEG 400 MCC / Silica Pardhi, Shivhare et al. 2010; 
Burra and Reddy 2012 
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Drug  Therapeutic class/ 
BCS class 
Liquid vehicle Carrier / Coating materials Reference 
Clofibrate                  
(liquid drug) 
Lipid lowering agent - MCC / Silica Spireas 2002 
Cyclosporine-A 
 
 
 
Immunosuppressive/ 
Class II 
Lauroglycol
®
 FCC, 
Maisine
®
 35-1, 
PEG-35 castor oil,  
PEG 400 
MCC / MAMS Zhao, Zhou et al. 2011 
Diazepam Antiepileptic, 
antianxiety agent/                    
Class II 
PEG 600 MCC / Silica Manogar, Hari et al. 2011 
 
Domperidone Antidopaminergic/ 
Class II 
Polysorbate 20, 
Polysorbate 40, 
Polysorbate 60, 
Polysorbate 80, PG, 
PEG 200, PEG 400 
MCC / Silica Ibrahim, El-Faham et al. 2011 
Escitalopram oxalate Antidepressant/Class II PG MCC / Silica Kumbhar, Mujgond et al. 2013 
Etoricoxibe NSAID/Class II PEG 400 MCC / Silica Yala, Srinivasan et al. 2012 
Ezetimibe Lipid lowering agent/ 
Class II 
PEG 400, Polysorbate 
80, Transcutol
®
 HP, 
Labrasol
®
   
MCC / Silica Khanfar, Salem et al. 2013 
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Drug  Therapeutic class/ 
BCS class 
Liquid vehicle Carrier / Coating materials Reference 
Famotidine Antiulcer/Class IV PG MCC / Silica Fahmy and Kassem 2008 
Fenofibrate Antihyperlipidemic/ 
Class II 
PG MCC / Silica Karmarkar, Gonjari et al. 2009 
Fenofibrate Antihyperlipidemic/  
Class II 
PG, PEG 600 MCC / Silica Sabale, Grampurohit et al. 2012 
Furosemide High-ceiling loop 
diuretic/Class IV 
PEG 400,                 
Synperonic
®
 PE/L81, 
Caprol
®
 PGE-860  
MCC / Silica Akinlade, Elkordy et al. 2010 
Furosemide 
 
High-ceiling loop 
diuretic/Class IV 
Polysorbate 80 MCC / Silica Burra and Galipelly 2010 
Gemfibrozil  Antilipidemic/Class II Polysorbate 80 MCC / Silica Spireas 2002 
 
Glibenclamide Antidiabetic/Class II PEG 400 MCC / Silica Darwish and El-Kamel 2001 
Glimepiride Antidiabetic/Class II PG MCC / Silica Singh, Prakash et al. 2011 
Glipizide Antidiabetic/Class II PG, PEG 200, 
PEG 400 
MCC / Silica Mahajan, Dhamne et al. 2011 
Griseofulvin Antifungal/Class II PEG 300 MCC, MAMS /                             
Colloidal silica, MAMS 
Hentzschel, Alnaief et al. 2011 
Griseofulvin Antifungal/Class II PEG 400 MCC / Silica Yadav and Yadav 2010 
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Drug  Therapeutic class/ 
BCS class 
Liquid vehicle Carrier / Coating materials Reference 
Hydrochlorothiazide Diuretic, 
antihypertensive/     
Class IV 
PEG 200 MCC / Silica Khaled, Asiri et al. 2001 
Hydrochlorothiazide Diuretic, 
antihypertensive/     
Class IV 
PEG 400 MCC / Silica Spireas 2002  
Hydrocortisone Corticosteroid/Class II PG MCC / Silica Spireas, Sadu et al. 1998;                 
Spireas 2002 
Ibuprofen NSAID/Class II PEG 300 MCC / Silica Hentzschel, Alnaief et al. 2010 
Ibuprofen NSAID/Class II PEG 400 MCC / Silica Chuahan, Patel et al. 2012 
Indomethacin NSAID/Class II  PG MCC / Silica Nokhodchi, Javadzadeh et al. 
2005 
Indomethacin NSAID/Class II PEG 400 MCC, DCP / HPMC Yadav and Yadav 2009 
Indomethacin NSAID/Class II PEG 200, Glycerin MCC / Silica Saeedi, Akbari et al. 2011 
Irbesartan Antihypertensive/    
Class II 
PEG 400 MCC / Silica Boghra, Patel et al. 2011 
Ketoprofen NSAID/Class II PG, Polysorbate 80 MCC, DCP / Silica Nagabandi, Tadikonda et al. 2011 
Ketoprofen NSAID/Class II PEG MCC, DCP, Starch, Lactose / 
Silica 
Nagabandi, Tadikonda et al. 2011 
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Drug  Therapeutic class/ 
BCS class 
Liquid vehicle Carrier / Coating materials Reference 
Lamotrigine Antiepileptic/Class II PEG 400 MCC / Silica Yadav and Yadav 2010 
Lansoprazole Proton-pump 
inhibitor/Class II 
Polysorbate 80 MCC / Silica Kasture, Gondkar et al. 2011 
Levothyroxine 
sodium 
Thyroid hormone/   
Class II 
Olive oil, Soybean oil MCC / Silica Spireas 2005 
Loratadine Antihistaminic/Class II PG MCC / Silica El-Hammadi and Awad 2011 
Meloxicam NSAID/Class II PG, PEG 400, 
Polysorbate 80 
MCC / Silica El-Gizawy 2007 
Meloxicam NSAID/Class II PEG 400 MCC / Silica Emmadi, Sanka et al. 2010 
Metaxalone Muscle relaxant/       
Class II 
PEG 400,                
Polysorbate 80, 
MCC  Spireas 2011 
Methyclothiazide Diuretic, 
antihypertensive/    
Class II 
PEG 400 MCC / Silica Spireas, Wang et al. 1999;  
Spireas 2002 
Naproxen  NSAID/Class II PEG 400,  
Cremophor
®
 EL, 
Synperonic
®
 PE/L61 
MCC / Silica Tiong and Elkordy 2009 
Nifedipine  Vasodilator/Class II PEG 400 MCC / Silica Spireas 2002 
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Drug  Therapeutic class/ 
BCS class 
Liquid vehicle Carrier / Coating materials Reference 
Nifedipine  Vasodilator/Class II PG, PEG 400, 
Polysorbate 80 
MCC / Silica Annapureddy, Preetha et al. 2013 
Nimesulide NSAID/Class II PG, PEG 400, 
Polysorbate 80 
MCC / Silica Hassan and El-Saghir 2011 
Pioglitazone HCl Antidiabetic/Class II  PG MCC / Silica Gandhi, Sawant et al. 2013 
Piroxicam NSAID/Class II Polysorbate 80 MCC / Silica Javadzadeh, Siahi et al. 2005; 
Javadzadeh, Siahi et al. 2007 
Piroxicam NSAID/Class II PG MCC / Silica Javadzadeh, Shariati et al. 2009 
Prednisolone Glucocorticoid/Class II PG, PEG 400, Glycerin, 
Polysorbate 80 
MCC / Silica Spireas and Sadu 1998 
Prednisone Glucocorticoid/         
Class II 
PG MCC / Silica Spireas 2002 
Repaglinide Antidiabetic/Class II Polysorbate 80 MCC / Calcium silicate El-Houssieny 2008;                             
El-Houssieny, Wahman et al. 
2010 
Rifampicin NSAID/Class II Polysorbate 80 MCC / Silica Rajesh, Pinkesh et al. 2013 
Rofecoxib NSAID/Class II PEG 600 MCC / Silica El-Say, Samy et al. 2010                      
Rosuvastatin 
calcium 
Cholesterol lowering 
agent/Class II 
PG, PEG 400, 
Polysorbate 80 
MCC / Silica Kapure, Pande et al. 2013                      
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Drug  Therapeutic class/ 
BCS class 
Liquid vehicle Carrier / Coating materials Reference 
Simvastatin Hypolipidemic/Class II PG MCC / Silica Burra, Kudikula et al. 2011 
Spironolactone Steroid/Class II PEG 400 MCC / Silica Spireas 2002 
Tamoxifen citrate Antiestrogenic/Class II PG MCC / Silica Walunj, Sharma et al. 2012 
Telmisartan Antihypertensive/            
Class II 
PEG 400 MCC / Silica Swamy and Shiny 2013 
Tocopherol acetate 
(liquid drug) 
Vitamin supplement - MCC, MAMS, Fujicalin
®
 / 
Colloidal silica, Calcium 
silicate, MAMS 
Hentzschel, Sakmann et al. 2011 
Valsartan  Antihypertensive/             
Class II 
PG, PEG, Glycerine MCC / Silica Lakshmi, Srinivas et al. 2011 
Valsartan  Antihypertensive/              
Class II 
PG MCC, Lactose, DCP / Silica Chella, Shastri et al. 2012 
     
Caprol
®
 PGE-860: 1,2,3-propanetriol homopolymer (9Z)-9-octadecenoate. 
Cremophor
®
 EL: Polyoxyl 35 castor oil. 
Fujicalin
®
: Spherically granulated dicalcium phosphate anhydrous.  
Labrasol
®
: Capryl capryol polyoxy glycerides. 
Lauroglycol
®
 FCC: Propylene glycol monolaurate (type 1). 
Maisine
®
 35-1: Glyceryl monolinoleate. 
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Synperonic
®
 PE/L61: Poloxamer 181. 
Synperonic
®
 PE/L81: Polyoxyethylene-polyoxypropylene block copolymer.  
Transcutol
®
 HP:  Diethylene glycol monoethyl ether.
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1.1.4 Liquid loading capacity of powders 
A powder can retain only limited amounts of liquid while maintaining acceptable flow 
and compression properties. To calculate the required amounts of powder excipients (carrier 
and coating materials) a mathematical approach for the formulation of LS systems has been 
developed by Spireas (Spireas and Sadu 1998; Spireas 2002). This approach is based on the 
flowable (Ф-value) and compressible (Ψ-number) liquid retention potential introducing 
constants for each powder/liquid combination. The Ф-value of a powder represents the 
maximum amount of a given non-volatile liquid that can be retained inside its bulk [w/w] 
while maintaining an acceptable flowability. The flowability may be determined from the 
powder flow or by measurement of the angle of repose.  
 
The Ψ-number of a powder is defined as the maximum amount of liquid the powder 
can retain inside its bulk [w/w] while maintaining acceptable compactability resulting in 
compacts of sufficient hardness with no liquid leaking out during compression. The 
compactability may be determined by the so-called “pactisity” which describes the maximum 
(plateau) crushing strength of a one gram tablet compacted at sufficiently high compression 
forces. The terms “acceptable flow and compression properties” imply the desired and thus 
preselected flow and compaction properties which must be met by the final LS formulation. 
 
Depending on the excipient ratio (R) of the powder substrate an acceptably flowing 
and compressible LS system can be obtained only if a maximum liquid load on the carrier 
material is not exceeded. This liquid/carrier ratio is termed “liquid load factor (Lf)” and is 
defined as the ratio between the weights of liquid formulation (W) and the carrier material (Q) 
in the system: 
 
Lf  = W / Q      
 
R represents the ratio between the weights of the carrier (Q) and the coating (q) 
material present in the formulation: 
 
19 
 
R = Q / q       
 
The Lf that ensures acceptable flowability  (
Φ
Lf ) can be determined by: 
 
Φ
Lf  =  Φ + φ ⋅(1/R)  
 
Where Φ and φ are the Ф-values of the carrier and coating materials, respectively 
(Spireas and Sadu 1998; Spireas 2002). 
 
Similarly, the Lf for production of LS systems with acceptable compactability (
Ψ
Lf) can 
be determined by: 
 
Ψ
Lf  =  Ψ + ψ ⋅(1/R)  
  
Where Ψ and ψ are the Ψ-numbers of the carrier and coating materials, respectively. 
 
The optimum liquid load factor (L0) required to obtain acceptably flowing and 
compressible LS systems are equal to either 
Φ
Lf or 
Ψ
Lf whichever represents the lower value. 
 
As soon as the L0 is determined, the appropriate quantities of carrier (Q0) and coating 
(q0) material required to convert a given amount of liquid formulation (W) into an acceptably 
flowing and compressible LS system may be calculated as follows: 
 
Q0 = W / L0      
and 
q0 = Q0 / R      
 
The validity and applicability of the above mentioned principles have been tested and 
verified by producing LS compacts possessing acceptable flow and compaction properties 
(Spireas 2002). 
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1.1.5 Preparation and optimization of LS systems  
The new LS technique may be applied to formulate liquid medications (i.e., oily liquid 
drugs and solutions, suspensions or emulsions of poorly water soluble solid drugs carried in 
non-volatile liquid vehicles) into powders suitable for tableting or encapsulation. Simple 
blending of such liquid medications with calculated quantities of a powder substrate consisting 
of certain excipients referred to as the carrier and coating powder materials, can yield dry 
looking, non adherent, free flowing and readily compressible powders (Spireas and Bolton 
1999). The liquid portion, which can be a liquid drug, a drug suspension or a drug solution in 
suitable non-volatile liquid vehicles, is incorporated into the porous carrier material. Once the 
carrier is saturated with liquid, a liquid layer is formed on the particle surface which is 
instantly adsorbed by the fine coating material particles. The coating material provides the 
conversion from a wet to a dry surface and gives the LS system desirable flow properties 
(Figure 1.2).  
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Figure 1.2 Schematic representation of liquisolid systems 
 
To prepare a LS system, first the drug is dispersed or dissolved in the non-volatile 
solvent, the carrier and coating material mixture in a ratio is then added to the liquid 
medication. The liquid medication is now converted to powder form. Various excipients such 
as disintegrants and lubricants may be added to the LS compacts (Figure 1.3). Before 
preparing into compacts pre-compression studies have to be performed.  
 
 
 
 
 
 
 
Liquid (liquid drug, drug 
solution, drug suspension) 
Carrier particles Incorporation of liquid 
Carrier saturated with 
liquid 
Liquid layer on particle surface 
Addition of coating 
particles 
Conversion from a wet to a dry 
surface 
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Figure 1.3 Schematic outline of the steps involved in the preparation of liquisolid systems 
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Carrier  
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Solid 
pharmaceutical drug 
Drug solution  
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Coating 
material 
FINAL 
FORMULATION 
By adding and mixing coating 
material, wet particles can be 
converted to dry looking, free 
flowing powders. 
Can be filled into CAPSULES or 
Can be compressed into TABLETS 
Addition of more 
excipient if necessary 
LIQUISOLID 
SYSTEM 
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The LS technology has been successfully applied to low dose, poorly water soluble 
drugs. The formulation of a high dose, poorly soluble drug is one of the limitations of the LS 
technology. As the release rates are directly proportional to the fraction of molecularly 
dispersed drug in the liquid formulation a higher drug dose requires higher liquid amounts for 
a desired release profile.   
 
Moreover, to obtain LS systems with acceptable flowability and compressibility, high 
levels of carrier and coating materials are needed. However, this results in an increase in tablet 
weight ultimately leading to tablet sizes which are difficult to swallow. Therefore, to 
overcome this and various other problems of the LS technology several formulation 
parameters may be optimized (Table 1.2).  
 
Table 1.2 Optimization of some formulation parameters for liquisolid 
 systems with immediate drug release 
Formulation parameter Optimization Effect 
Liquid vehicle  High drug solubility in the 
vehicle 
Increased fraction of the 
molecularly dispersed drug (FM) 
Carrier and coating 
materials 
High specific surface area Increased liquid load factor (Lf) 
Excipient ratio (R) High R value Fast disintegration, inhibition of 
precipitation 
 
1.1.6 Characterization of LS systems  
1.1.6.1     Preformulation studies 
Before formulating the LS systems preformulation studies should be performed first, 
these include; solubility studies, determination of angle of slide, calculation of liquid load 
factor, determination of flowable liquid retention potential and LS compressibility test. 
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Solubility studies 
To select the best non-volatile solvent for dissolving or suspending the drug in liquid 
medication, solubility studies are carried out by preparing saturated solutions of drug by 
adding excess of drug into non-volatile solvents and shaking them on shaker for specific time 
period under constant vibration. After this, the solutions are filtered and analyzed (Kulkarni, 
Aloorkar et al. 2010).  
 
Determination of angle of slide 
Powder excipient or its mixture is accurately weighed and placed at one end of a metal 
plate (with a polished surface). This end is raised gradually until the plate makes an angle with 
the horizontal at which the powder is about to slide. This is called the angle of slide (Ɵ). It is 
taken as a measure for the flow properties of powders. An angle of slide corresponding to 33
0
 
is regarded as optimal flow behaviour (Spireas, Jarowski et al. 1992). 
 
Calculation of liquid load factor  
Liquid load factor (Lf) is defined as the ratio of weight of the liquid medication (W) to 
weight of the carrier material (Q) and it can be determined by using the following formula 
(Spireas and Bolton 2000; Spireas 2002). 
 
Lf  = W / Q      
 
W= Weight of liquid medication 
Q= Weight of carrier material 
 
Determination of flowable liquid retention potential 
The term "flowable liquid retential potential" (Φ value) of a powder material describes 
its ability to retain a specific amount of liquid while maintaining good flow properties. The Φ 
value is defined as the maximum weight of liquid that can be retained per unit weight of the 
powder material in order to produce an acceptably flowing liquid/powder admixture (Tayel, 
Soliman et al. 2008). 
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LS compressibility test 
LS compressibility test is used to determine Φ values and involves steps such as 
preparing carrier-coating material admixture systems, preparing several uniform liquid or 
powder admixtures, compressing each liquid or powder admixtures to tablets, assessing 
average hardness, determination of average liquid content of crushed tablets, as well as 
determining plasticity, sponge index and Φ value and Lf value (Spireas and Bolton 1999; 
Spireas 2002). 
 
1.1.6.2     Evaluation of LS systems 
1.1.6.2.1     Pre-compression evaluations 
In order to ensure the suitability of the selected excipients, Differential Scanning 
Calorimetry (DSC), X-Ray Diffraction (XRD), Fourier Transformed Infrared Spectroscopy 
(FTIR) and Scanning Electron Microscopy (SEM) studies are performed. In addition, 
flowability studies are also carried out to select the optimal formula for compression.  
 
Differential Scanning Calorimetry (DSC) 
It is used to determine the interactions between drug and excipients, which indicates 
the success of stability studies. The drug has a characteristic peak, absence of this peak in DSC 
thermogram indicates that the drug is in the form of solution in liquid formulation and it is 
molecularly dispersed within the system (Fahmy and Kassem 2008). DSC studies showed that 
clozapine exhibits a sharp endothermic peak at 182.67
0
 (Govda, Ram et al. 2012). 
 
 
X-Ray Diffraction (XRD) 
For characterization of the crystalline state, the XRD patterns are determined for drug, 
excipients used in formulation, physical mixture of drug and excipients, finally for the 
prepared LS system (Javadzadeh, Navimipour et al. 2007). Absence of constructive specific 
peaks of the drug in the LS X-ray diffractogram indicate that drug has almost entirely 
converted from crystalline to amorphous or solubilized form. Such lack of crystallinity in the 
LS system is understood to be as a result of drug solubilization in the liquid vehicle i.e., the 
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drug has formed a solid solution within the carrier matrix. This amorphization or solubilization 
of drug in the LS system may contribute to the consequent improvement in the apparent 
solubility and therefore the dissolution rate of the drug (Fahmy and Kassem 2008). XRD 
pattern of pure clozapine showed a characteristic peaks at 2θ0 = 10.52, 17.39, 19.36, 19.73, 
21.05, 21.44, 23.09 and 23.72 (Govda, Ram et al. 2012). 
 
Scanning Electron Microscopy (SEM) 
SEM is utilized to assess the morphological characteristics of the raw materials and 
drug-carrier systems
 
(Fahmy and Kassem 2008). 
 
Fourier Transformed Infrared Spectroscopy (FTIR) 
FTIR studies are performed to determine the chemical interaction between the drug 
and excipients used in the formulation. The presence of drug peaks in the formulation and 
absence of extra peaks suggest that there are no chemical interactions between the drug and 
the carrier when formed as LS system (Yadav, Nighute et al. 2009). 
 
Contact angle measurement 
For assessment of wettability, contact angle of LS tablets is measured according to the 
imaging method. The commonly used method is to measure contact angle directly for a drop 
of liquid resting on a plane surface of the solid, the so-called imaging method. A saturated 
solution of the drug in dissolution media is prepared and a drop of this solution is put on the 
surface of tablets. The contact angles are calculated by measuring the height and diameter of 
sphere drop on the tablet
 
(Javadzadeh, Navimipour et al. 2007). 
 
Flow behaviour 
 Flow property of a powder is of major importance in the production of tablet dosage 
forms in order to attain a uniform feed and reproducible filling of tablet dies. Angle of repose, 
Carr’s index, Hausner’s ratio and compressibility index are used in order to ensure the flow 
properties of the powders (Banker and Anderson 1987). 
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1.1.6.2.2     Post-compression evaluations 
 The formulated LS systems are evaluated for post-compression parameters such as;  
-  Weight variation 
- Drug content / content uniformity 
- Hardness 
- Thickness and diameter 
- Friability 
- Disintegration 
- In vitro dissolution studies 
- In vivo evaluation 
- Stability studies 
(Kavitha, Raju et al. 2011; Lakshmi, Kumari et al. 2012) 
 
Evaluation parameters of the tablets mentioned in the Pharmacopoeias need to be 
assessed, along with some special tests are discussed here: 
 
Stability studies 
To obtain information on the stability of LS systems, the effects of storage on the 
release profile and the crushing strength of LS compacts were investigated. Stability studies of 
LS systems containing atorvastatin calcium (40 °C / 75% RH, 6 months) (Gubbi and Jarag 
2010), carbamazepine (25 °C / 75% RH, 6 months) (Javadzadeh, Navimipour et al. 2007), 
ezetimibe (30 
0
C / 60% RH, 1 month) (Khanfar, Salem et al. 2013), glimepiride (25 °C / 75% 
RH, 6 months) (Singh, Prakash et al. 2011), hydrocortisone (ambient conditions, 10 months) 
(Spireas 2002), indomethacin (25 °C / 75% RH, 12 months) (Javadzadeh, Siahi et al. 2007),  
naproxen (20 °C / 76% RH, 4 weeks) (Tiong and Elkordy 2009) and piroxicam (25 °C / 75% 
RH, 6 and 9 months, respectively) (Javadzadeh, Siahi et al. 2007;  Javadzadeh, Shariati et al. 
2009) showed that storage at different conditions neither had an effect on the hardness nor on 
the release profiles of LS compacts. This indicates that the LS technology is a promising 
technique to enhance the release rate without having any physical stability issues. 
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In vivo evaluation 
The LS technology is a promising approach for the enhancement of drug release of 
poorly water soluble or practically water insoluble drugs. Bioavailability assessment is 
required for LS technique, because it was proved that enhancing the drug releases from the 
dosage form by determination of in vitro release studies. So, this parameter should establish 
for determination of the efficacy of the formulation. Some researchers have been evaluated in 
vivo absorption and bioavailability characteristics of LS compacts as described in Table 1.3.  
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Table 1.3 List of some in vivo studies 
Drug  Therapeutic class Results Reference 
Carbamazepine Antiepileptic (sodium 
channel blocker) 
In vivo testing demonstrated that the bioavailability of 
carbamazepine from the LS capsules was enhanced by 
182.7%. The study also showed that a lower drug dose can 
be administrated using LS capsules to achieve similar 
clinical effects but minimize the associated adverse effects.  
Chen, Wang et al. 2012 
Pioglitazone HCl Antidiabetic It was found that the relative bioavailability of pioglitazone 
HCl from the LS tablets was significantly higher than that 
from the commercial tablets. In addition, the in vivo 
reduction of blood glucose level through the optimized LS 
formula was greater than that of marketed product. 
Gandhi, Sawant et al. 2013 
Repaglinide Antidiabetic The study showed that the relative bioavailability of 
repaglinide from the LS compacts was significantly higher 
than that from the commercial tablets. The results of the 
glucose tolerance test showed that the blood glucose level 
was decreased significantly after the commercial drug 
(percent change, 18.1%) while in groups treated with the LS 
formulation the decrease was highly significant with a 
percent change of 29.98%. 
El-Houssieny, Wahman et al.  
2010 
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1.1.7 Sustained release with LS formulations 
Development of sustained release oral dosage forms is beneficial for optimal therapy in 
terms of efficacy, safety and patient compliance. Ideally, a controlled release dosage form will 
provide therapeutic concentration of the drug in the blood that is maintained throughout the 
dosing interval. To achieve this aim, several methods have been developed such as preparation 
of salt form of drug, coating with special materials and incorporation of drugs into 
hydrophobic carriers. LS technique is a novel method that can change the dissolution rate of 
drugs (Javadzadeh, Musaalrezaei et al. 2008). If hydrophobic carriers such as acrylic resin 
polymers (Eudragit
®
 RL and RS) are used instead of hydrophilic carriers in LS systems, 
sustained release formulations can be obtained. Some drugs have been formulated as LS 
sustained release systems. Different liquid vehicles, carriers and coating materials were used 
to formulate these drug delivery systems (Table 1.4). 
 
 
 
 
 
 
 
 
 
 
31 
 
Table1.4 (a) List of some of developed sustained release liquisolid systems 
Drug  Therapeutic 
class 
Liquid vehicle  Carrier material  Coating 
material 
Additional 
retardant agent 
Reference 
Lornoxicam NSAID  Polysorbate 80  
 
MCC, Eudragit
®
 RL PO, 
Eudragit
®
 S-100, 
Chitosan, Sodium CMC 
Silica - Ganesh, Deecaraman 
et al. 2011 
Metoprolol 
succinate 
Antihypertensive, 
antiarrhythmic  
Polysorbate 80  
 
MCC Silica HPMC Jagannath, Maroti et 
al. 2013 
Propranolol 
HCl 
β-adrenergic 
blocking agent  
Polysorbate 80  Eudragit
®
 RL and RS Silica HPMC (4000 
mPa.s) 
Javadzadeh, 
Musaalrezaei et al. 
2008 
Theophylline Antiasthmatic Polysorbate 80 Eudragit
®
 RL and RS Silica HPMC E4M Nokhodchi, Aliakbar 
et al. 2010 
Tramadol HCl Opioid analgesic  PG MCC Silica HPMC K4M     
 
Karmarkar, Gonjari 
et al. 2010 
Venlafaxine 
HCl 
Antidepressant PG, PEG 400, 
polysorbate 80 
Eudragit
®
 RS PO Silica HPMC Khanfar, Salem et al. 
2013 
Eudragit
® 
RL: Acrylic resin RL polymer, Eudragit
®
 RL PO: A copolymer of ethyl acrylate, methyl methacrylate and a low content of 
methacrylic acid ester with quaternary ammonium groups, Eudragit
®
 RS: Acrylic resin RS polymer, Eudragit
® 
S-100: Anionic copolymer 
based on methacrylic acid and methyl methacrylate, HPMC: Hydroxypropylmethyl cellulose, Sodium CMC: Sodium carboxymethyl 
cellulose. 
32 
 
Table1.4 (b) List of some of developed sustained release liquisolid systems 
Drug  Results Reference 
Lornoxicam The results showed retardation in the release rate of the drug from the LS compacts 
and the kinetic studies showed that the sustained release LS formulations followed 
zero-order.  
Ganesh, Deecaraman et al. 2011 
Metoprolol 
succinate 
The study showed the LS technique can be optimized for the production of sustained 
release matrices of water-soluble drugs. LS formulations containing Polysorbate 80 
followed zero-order release kinetics. In this study, wet granulation technique showed 
more retardation properties compared to direct compression technique.   
Jagannath, Maroti et al. 2013 
Propranolol HCl Sustained release LS tablets prepared by wet granulation technique showed greater 
retardation properties in comparison with conventional matrix tablets and most of LS 
formulations followed zero-order release pattern. 
Javadzadeh, Musaalrezaei et  al. 
2008 
Theophylline The prepared LS compacts showed more sustained release behaviour as compared to  
simple sustained release matrix tablets and the results suggested that zero-order release 
can be achieved with LS formulations. 
Nokhodchi, Aliakbar et al. 2010 
Tramadol HCl The prepared LS compacts of water-soluble drug, tramadol HCl showed more 
sustained release behaviour as compared to marketed sustained release formulations. 
The release profiles of drug followed the Peppas model. 
Karmarkar, Gonjari et al. 2010 
 
Venlafaxine 
HCl 
The prepared LS formulations have shown a better sustained release effect in 
comparison with directly compressed tablets. The type of liquid vehicle was to found 
to affect the drug release significantly.   
Khanfar, Salem et al. 2013 
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1.1.8 Advantages and limitations of LS systems 
Some advantages and limitations of LS systems are listed in Table 1.5. 
 
Table 1.5 Advantages and limitations of liquisolid systems 
Advantages Limitations 
Poorly water soluble or water insoluble drugs can be 
formulated into LS systems. 
This technique is only for slightly*/very 
slightly water soluble** and practically 
water insoluble*** drugs. 
Better availability of an orally administered poorly 
water soluble drug is achieved when the drug is in 
solution form. 
In order to achieve acceptable 
flowability and compactability for LS 
powder formulation, high levels of 
carrier and coating materials should be 
added. This will increase the weight of 
tablets to above one gram which makes 
them difficult to swallow.  
Optimized rapid release LS tablets or capsules of 
poorly water soluble drugs exhibit enhanced in vitro 
and in vivo drug release as compared to their 
commercial counterparts. 
The LS systems have drug loading 
capacities and they require high 
solubility of drug in non-volatile liquid 
vehicles.  
Can be applied to formulate liquid medications such as 
oily liquid drugs. 
 
Enhanced bioavailability can be obtained as compared 
to conventional tablets. 
 
Drug release can be modified using suitable 
formulation ingredients. 
 
Can be used in controlled drug delivery and zero-order 
release can be obtained. 
 
Drug can be molecularly dispersed in the formulation.  
Capability of industrial production is also possible.  
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Advantages Limitations 
Their production cost is lower than that of soft gelatine 
capsules, because the production of LS systems is 
similar to that of conventional tablets. 
 
 
(Saharan, Kukkar et al. 2009; Saharan, Kukkar et al. 2009; Kulkarni, Aloorkar et al. 2010; 
Bindu, Kusum et al. 2010; Sharma and Jain 2010; Gavali, Pacharane et al.  2011; Rajesh, 
Rajalakshmi et al. 2011; Burra, Yamsani et al. 2011) 
 
* Slightly soluble: From 100 to 1000 parts solvent needed to dissolve 1 part solute 
** Very slightly soluble: From 1000 to 10 000 parts solvent needed to dissolve 1 part solute 
*** Practically insoluble or insoluble: More than 10 000 parts solvent needed to dissolve 1 
part solute (USP36-NF31, 2013).  
 
 
 
1.1.9 Conclusion 
LS technique is a promising alternative method for formulation of poorly water soluble 
or water insoluble solid drugs and liquid lipophilic drugs. LS compacts refer to formulations 
formed by conversion of solid state to liquid state, drug suspensions or drug solutions in non-
volatile solvents into dry, non-adherent, free flowing and compressible powder mixtures by 
blending the suspension or solution with selected carrier and coating materials. When the drug 
within the LS system is completely dissolved in the liquid vehicle, it is located in the powder 
substrate still in a solubilized state. Already the dissolved drug only needs to diffuse out of the 
formulation and the liquid component of the formulation act as a solubilizing aid to facilitate 
the wetting and dissolution of the undissolved particles. Thus, this shows improved release 
rates and greater bioavailability. This technique is also used to design sustained release 
systems by using hydrophobic carriers in LS systems.  
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1.2 Orally disintegrating tablets (ODTs) 
1.2.1 Overview 
For the past one decade, there has been an enhanced demand for more patient-friendly 
and compliant dosage forms. As a result, the demand for developing new technologies has 
been increasing annually (Hirani, Rathod et al. 2009). Since the development cost of a new 
drug molecule is very high, efforts are now being made by pharmaceutical companies to focus 
on the development of new drug dosage forms for existing drugs with improved safety and 
efficacy together with reduced dosing frequency and the production of more cost effective 
dosage forms.  
 
For most therapeutic agents used to produce systemic effects, the oral route still 
represents the preferred way of administration, owing to its several advantages and high 
patient compliance compared to many other routes (Valleri, Mura et al. 2004). Tablets and 
hard gelatin capsules constitute a major portion of drug delivery systems that are currently 
available. However, many patient groups such as the elderly, children and patients who are 
mentally retarded, uncooperative, nauseated or on reduced liquid-intake/diets have difficulties 
swallowing these dosage forms. Those who are traveling or have little access to water are 
similarly affected (Hanawa, Watanabe et al. 1995; Mallet 1996; Porter 2001). 
 
To fulfill these medical needs, pharmaceutical technologists have developed a novel 
oral dosage form known as “Orally Disintegrating Tablets (ODT)” which disintegrate rapidly 
in saliva, usually in a matter of seconds, without the need of water. Drug dissolution and 
absorption as well as onset of clinical effect and drug bioavailability may be significantly 
greater than those observed from conventional dosage forms (Seager 1998; Bradoo, Shahani et 
al. 2001; Sreenivas, Dandagi et al. 2005). 
 
Although chewable tablets have been on the market for some time, they are not the 
same as the new ODTs. Patients for whom chewing is difficult or painful can use these new 
tablets easily. ODTs can be used easily in children who have lost their primary teeth but do not 
have full use of their permanent teeth (Mizumoto, Masuda et al. 2005).  
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Recent market studies indicate that more than half of the patient population prefers 
ODTs to other dosage forms (Deepak 2004) and most consumers would ask their doctors for 
ODTs (70%), purchase ODTs (70%) or prefer ODTs to regular tablets or liquids (>80%) 
(Brown 2003). 
 
ODTs have been developed for numerous indications ranging from migraines (for 
which rapid onset of action is important) to mental illness (for which patient compliance is 
important for treating chronic indications such as depression and schizophrenia) (Ghosh, 
Chatterjee et al. 2005).  
 
1.2.2 Description of orally disintegrating (OD) dosage forms 
All fast disintegrating tablets approved by United States Food and Drug 
Administration (US FDA) are classified as “ODTs”. European Pharmacopoeia adopted the 
term “orodispersible tablets” for tablets that dispersed or disintegrate in less than 3 min in the 
mouth before swallowing. Such a tablet disintegrates into smaller granules or gel like 
structure, allowing easily swallowing by patients. As per recent US FDA guideline on ODT, 
disintegration time of ODT should have an in vitro disintegration time of approximate 30 s or 
less, when based on United States Pharmacopoeia (USP) disintegration test method or 
alternative.  
 
ODTs are different from conventional sublingual tablets, buccal tablets and lozenges, 
which require more than a minute to dissolve in oral cavity. Different OD dosage forms are as 
follows: 
 
Fast dissolving tablets and ODTs: Fast dissolving tablet (also known as fast 
dissolving multiparticulate, rapid dissolving, mouth dissolving, fast melting or orodispersible 
tablet) is an oral tablet that does not require water for swallowing (Hirani, Rathod et al. 2009).  
 
Recently, European Pharmacopoeia has used the term orodispersible tablets. This may 
be defined as uncoated tablets intended to be placed in the mouth where they disperse readily 
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within 3 min before swallowing (Fu, Yang et al. 2004). USP has also approved these dosage 
forms as orodispersible tablets. Thus, orodispersible tablets are solid unit dosage forms like 
conventional tablets, but are composed of superdisintegrants, which help them to dissolve the 
tablets within a minute in the mouth in the presence of saliva without any difficulty of 
swallowing. It offers several advantages with respect to its stability, administration without 
water, accurate dosing, easy manufacturing, small packaging size and handling (Seager 1998; 
Habib, Khankari et al. 2000; Brown 2003; Bandari, Mittapalli et al. 2008). Its ease of 
administration in the population especially for pediatric, geriatric or any mentally retarded 
persons makes it a very popular dosage form. Due to the presence of superdisintegrants, it gets 
dissolved quickly, resulting in rapid absorption of drug which in turn provides rapid onset of 
action (Behnke, Sogaard et al. 2003). Since the absorption is taking place directly from the 
mouth, so, bioavailability of the drug increases (Clarke, Brewer et al. 2003). Drugs present in 
orodispersible tablets are also not suffering from first pass metabolism. This type of drug 
delivery is becoming popular day by day due to its numerous advantages. 
 
US FDA Center for Drug Evaluation and Research (CDER) Nomenclature Standards 
Committee developed the following definition for an ODT as a new dosage form in 1998: “A 
solid dosage form containing medicinal substances which disintegrates rapidly, usually within 
a matter of seconds, when placed upon the tongue.” (US FDA CDER 2008). The drug is 
released, dissolved or dispersed in the saliva and then swallowed and absorbed across the GIT. 
 
Freeze-dried wafer: It is a quick-dissolving, thin matrix that contains a medicinal 
agent that does not need water for swallowing. This fragile dosage form requires unit-dose 
packaging to ensure physical stability. The wafer disintegrates instantaneously in the oral 
cavity and releases drug, which dissolves or disperses in the saliva. The saliva is swallowed 
and the drug is absorbed across the GIT (Dobetti 2000). 
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1.2.3   Selection of drug candidates 
Several factors must be considered when selecting drug candidates for delivery as 
ODT dosage forms. In general, an ODT is formulated as a bioequivalent line extension of an 
existing oral dosage form. Under this circumstance, it is assumed that the absorption of a drug 
molecule from the ODT occurs in the postgastric GIT segments, similar to the conventional 
oral dosage form. But this scenario may not always be the case. An ODT may have varying 
degrees of pregastric absorption and thus, the pharmacokinetic (PK) profiles will vary (Lies, 
Atherton et al. 1993).  Therefore, the ODT will not be bioequivalent to the conventional oral 
dosage form. For example, ODT formulations of selegiline, apomorphine and buspirone have 
significantly different PK profiles compared with the same dose administered in a 
conventional dosage form (Ostrander 2003; Pfister and Ghosh 2005). 
 
It is possible that these differences may, in part, be attributed to the drug molecule, 
formulation or a combination of both. If significantly higher plasma levels have been 
observed, pregastric absorption leading to the avoidance of first pass metabolism may play an 
important role. This situation may have implications for drug safety and efficacy, which may 
need to be addressed and assessed in a marketing application for an ODT. For example, safety 
profiles may be improved for drugs that produce a significant amount of toxic metabolites 
mediated by first pass liver metabolism and gastric metabolism and for drugs that have a 
substantial fraction of absorption in the oral cavity and segments of the pregastric GIT. Drugs 
having ability to diffuse and partition into the epithelium of the upper GIT (log P > 1 or 
preferable > 2); and those able to permeate oral mucosal tissue are considered ideal for ODT 
formulations. Patients who concurrently take anticholinergic medications may not be the best 
candidates for these drugs. Similarly, patients with Sjögren’s syndrome or dryness of the 
mouth due to decreased saliva production may not be good candidates for these tablet 
formulations. Drugs with a short half-life and frequent dosing, drugs which are very bitter or 
otherwise unacceptable taste because taste masking can’t be achieved or those which require 
controlled or sustained release are unsuitable candidates of rapidly dissolving oral dosage 
forms (Hirani, Rathod et al. 2009). 
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Researchers have formulated ODTs for various categories of drugs used for therapy in 
which rapid peak plasma concentration is required to achieve the desired pharmacological 
response. These include neuroleptics, cardiovascular agents, analgesics, antiallergics, 
antiepileptics, anxiolytics, sedatives, hypnotics, diuretics, antiparkinsonism agents, 
antibacterial agents, lipid regulating agents, etc. (Sharma 2008). 
 
1.2.4 Excipients used for the preparation of ODTs 
1.2.4.1     Overview 
 Mainly seen excipients in orally disintegrating dosage forms are diluents, 
superdisintegrants, sweeteners, flavoring agents, lubricants etc. To formulate orally 
disintegrating dosage forms, superdisintegrants and sweetening agents play an important role.  
 
1.2.4.2   Superdisintegrants 
Superdisintegrants increase the rate of disintegration and hence the dissolution rate. 
For the success of fast dissolving tablet, the tablet having quick dissolving property which is 
achieved by using the superdisintegrants (Nagar, Singh et al. 2011). SSG, CCS, pregelatinized 
starch, CP etc. are most commonly used disintegrants (Rajesh, Rajalakshmi et al. 2011). 
 
Crospovidone (CP) quickly wicks saliva into the tablet to generate the volume 
expansion and hydrostatic pressures necessary to provide rapid disintegration in the mouth. 
Unlike other superdisintegrants, which rely principally on swelling for disintegration, CP uses 
a combination of swelling and wicking. CP disintegrants are highly compressible materials as 
a result of their unique particle morphology (Mohanachandran, Sindhumol et al. 2011). 
 
1.2.4.3   Sweetening agents 
There are various drugs which do not taste good. Since ODTs dissolve in mouth, so 
proper taste masking is very much essential, especially in the case of bitter taste drugs. 
Various approaches have been explored in order to mask the bitter or any other bad taste of the 
drugs which include addition of sweeteners and flavors or encapsulating the unpleasant drugs 
40 
 
into the microparticles or by the adjustment of pH. The most popular and general approach is 
the addition of sweeteners and flavors (Day and Maiti 2010). Artificial sweeteners such as 
aspartame, sodium saccharin and bulking agents such as dextrose, sucrose, mannitol, sorbitol, 
xylitol etc. are commonly used for taste masking.  
 
 Sodium saccharin (SS) is an intense sweetening agent used in pharmaceutical 
formulations such as tablets, powders, suspensions, liquids etc. SS considerably more soluble 
in water than saccharin and is more frequently used in pharmaceutical formulations. Its 
sweetening power is approximately 300–600 times that of sucrose. SS enhances flavor 
systems and may be used to mask some unpleasant taste characteristics. 
 
SS is successfully used as sweetening-taste masking agent in orodispersible tablet 
preparation of drugs such as carbamazepine (Swamy, Shahidulla et al. 2008), domperidone 
(Islam, Haider et al. 2011), metrodinazole (Mohire, Yadav et al. 2009) etc.  
 
 Mannitol has a sweet taste, approximately as sweet as glucose and half as sweet as 
sucrose and imparts a cooling sensation in the mouth. Mannitol is widely used in 
pharmaceutical formulations and food products. In pharmaceutical preparations it is primarily 
used as a diluent (10–90% w/w) in tablet formulations, where it is of particular value since it is 
not hygroscopic and may thus be used with moisture sensitive active ingredients. Mannitol 
may be used in direct compression tablet applications,
 
for which the granular and spray dried 
forms are available or in wet granulations. It is also used as a sweetening agent. 
 
Pearlitol
®
 SD 200 is granulated mannitol, slightly sweet tasting, crystalline powder. It 
has a unique blend of exceptional physical and chemical stability. It has properties like 
flowable, excellent compressibility, non-hygroscopic, excellent chemical stability. Pearlitol 
SD dissolves very rapidly because of its porous crystalline particles (Chaudhary, Chaudhary et 
al. 2010). 
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Mannitol is successfully used as a sweetening agent in orodispersible tablet preparation 
of drugs such as levocetirizine (Gandhi, Mundhada et al. 2011), meloxicam (Singh and Singh 
2009), metoprolol tartrate (Shailaja, Latha et al. 2012), valsartan (Ibrahim and El-Setouhy 
2010) etc. 
 
1.2.5   Methods of preparation of ODTs 
There are several methods for the preparation of ODTs, but the prepared products vary 
in their properties depending on the method of preparation. The properties in which they vary 
are mechanical strength of the tablets, swallowability, bioavailability, drug dissolution in 
saliva, stability and to some extent taste (Bandari, Mittapalli et al. 2008). Various process of 
manufacturing of ODTs are molding, compaction, spray-drying, freeze-drying, cotton candy, 
mass extrusion and some special methods are melt granulation, phase transition, sublimation 
and effervescent techniques.  
 
Molding: Tablets formed by molding process are highly porous in structure, resulting 
in high rate of disintegration and dissolution. This process includes moistening, dissolving or 
dispersing the drugs with a solvent then molding the moist mixture into tablets by applying 
lower pressure in compression molding, but always lower than the conventional tablet 
compression. The powder mixture may be sieved prior to the preparation in order to increase 
the dissolution (Dobetti 2000). Molded tablets have low mechanical strength, which results in 
erosion and breakage during handling. 
 
Compaction: Conventional methods for the preparation of tablets such as dry 
granulation, wet granulation and direct compression are also exist for the preparation of ODTs. 
Some superdisintegrants which are used during preparation of ODTs are CP, CCS, SSG, 
sodium alginate and acrylic acid derivatives (Ozeki T., Yasuzawa et al. 2003; Yang, Fu et al. 
2004). Baclofen orodispersible tablets were prepared by direct compression method using CP 
and SSG as superdisintegrants (Radke, Jadhav et al. 2009). Even orodispersible tablets of 
carbamazepine were prepared by this method having MCC and CP (Swamy, Shahidulla et al. 
2008). In all the cases it has been found that preparation by compression method along with 
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addition of superdisintegrants in correct concentration obey all the properties of ODTs 
(Swamy, Shahidulla et al. 2008; Radke, Jadhav  et al. 2009). 
 
Spray-drying: ODTs are made up of hydrolyzed or unhydrolyzed gelatin as 
supporting agent for matrix, mannitol as bulk agent and SSG or CCS as disintegrating agent. 
Sometimes in order to improve the disintegration and dissolution, citric acid and sodium 
bicarbonate are used. Finally, the formulation is spray-dried in a spray-drier. ODTs prepared 
through this method are disintegrated in less than 20 s (Allen and Wang 2001). 
 
Freeze-drying: This is a very popular process for the preparation of ODTs. Tablets 
prepared by this process have low mechanical strength, poor stability at higher temperature 
and humidity, but glossy amorphous structure resulting in highly porous, light weight product. 
There are various patents on this particular technology (Habib, Khankari et al. 2000). 
 
Melt granulation: It is a unique method for the preparation of ODTs by incorporating 
superpolystate (Abdelbary, Prinderre et al. 2004). Superpolystates are hydrophilic waxy 
binders with a melting point 33-37 °C and hydrophilic-lipophilic balance (HLB) value is 9. 
They play a dual role as a binder that increases the physical resistance of the tablets and also 
as a disintegrant, which helps the tablet to melt in the mouth and solubilize rapidly leaving no 
residue in the mouth.  
 
Cotton candy process: This process is so named as it utilizes a unique spinning 
mechanism to produce floss-like crystalline structure, which mimic cotton candy. Cotton 
candy process involves formation of matrix of polysaccharides or saccharides by simultaneous 
action of flash melting and spinning. The matrix formed is partially recrystallized to have 
improved flow properties and compressibility. This candy floss matrix is then milled and 
blended with active ingredients and excipients and subsequently compressed to ODT. This 
process can accommodate high doses of drug and offers improved mechanical strength. 
However, high-process temperature limits the use of this process (Meyers, Battist et al. 1995). 
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Mass extrusion: This technology involves softening the active blend using the solvent 
mixture of water soluble PEG and methanol and subsequent expulsion of softened mass 
through the extruder or syringe to get a cylinder of a product into even segments using heated 
blade to form tablets (Gupta, Mittal et al. 2012). 
 
Phase transition process: Kuno et al. investigated this process by compressing 
powder containing two sugar alcohols (Kuno, Kojima et al. 2005). One with high and another 
with low melting point and they are heated at a temperature between their melting points and 
then compressed finally in order to get the tablets. Example of sugar alcohols are erythriol 
(melting point: 122 °C), xylitol (melting point: 93-95 °C), trehalose (melting point: 97 °C), 
and mannitol (melting point: 166 °C). After heating, tablet hardness is increased due to an 
increase in interparticle bonds or the bonding surface area in tablets induced by phase 
transition of lower melting point sugar alcohol. 
 
Sublimation: In this process, subliming material “camphor” is used. It is sublimed in 
vacuum at 80 °C for 30 min after preparation of tablets. Here, also tablets prepared are porous 
in nature. In conventional types, sometimes rapid disintegration does not occur. Therefore, in 
order to improve porosity, volatile substance camphor is added in the preparation, which gets 
sublimed from the formed tablet (Koizumi, Watanabe et al. 1997). 
 
Effervescent method: ODTs are also prepared by effervescent method by mixing 
sodium bicarbonate and tartaric acid of concentration 12% (w/w) along with 
superdisintegrants like pregelatinized starch, SSG, CP and CCS. First, sodium bicarbonate and 
tartaric acid are preheated at a temperature of 80 °C to remove absorbed/residual moisture and 
thoroughly mixed in the mortar to get a uniform powder and then added to other ingredients. 
Finally, the blends are compressed to the tablets (Kaushik, Dureja et al. 2004; Swamy, Divate 
et al. 2009). 
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1.2.6 Evaluation of ODTs 
Evaluation parameters of tablets mentioned in the Pharmacopoeias need to be assessed, 
along with some special tests are discussed here. 
 
Hardness 
A significant strength of ODT is difficult to achieve due to the specialized processes 
and ingredients used in the manufacturing. The limit of hardness for the ODT is usually kept 
in a lower range to facilitate early disintegration in the mouth. The hardness of the tablet may 
be measured using conventional hardness testers (Velmurugan and Sundar 2010). 
 
Friability 
To achieve % friability within limits for an ODT is a challenge for a formulator since 
all methods of manufacturing of ODTs are responsible for increasing the % friability values. 
Thus, it is necessary that this parameter should be evaluated and the results are within bound 
limits (Velmurugan and Sundar 2010). 
 
Wetting time and water absorption ratio 
Wetting time of dosage form is related to with the contact angle. Wetting time of the 
ODT is another important parameter, which needs to be assessed to give an insight into the 
disintegration properties of the tablet. Lower wetting time implies a quicker disintegration of 
the tablet. The wetting time of the tablets can be measured by using the simple procedure 
(Gohel, Patel et al. 2004). Five circular tissue papers of 10 cm diameter are placed in a 
petridish. 10 mL of water soluble dye solution is added to a petridish. A tablet is carefully 
placed on the surface of the tissue paper. The time required for water to reach upper surface of 
the tablet is noted as the wetting time.  
 
For measuring water absorption ratio the weight of the tablet before keeping in the 
petridish is noted (Wb). The wetted tablet from the petridish is taken and reweighed (Wa). The 
water absorption ratio (R) can be the determined according to the following equation. 
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R = 100 (Wa-Wb) / Wb 
 
Moisture uptake studies 
Moisture uptake studies for ODT should be conducted to assess the stability of the 
formulation. Ten tablets from each formulation are kept in a dessicator over calcium chloride 
at 37 
0
C for 24 hrs. The tablets are then weighed and exposed to 75% RH, at room temperature 
for 2 weeks. Required humidity is achieved by keeping saturated sodium chloride solution at 
the bottom of the dessicator for 3 days. One tablet as control (without superdisintegrants) is 
kept to assess the moisture uptake due to other excipients. Tablets are weighed and the 
percentage increase in weight was recorded (Velmurugan and Sundar 2010). 
 
Disintegration test 
The ODT has remarkable disintegration properties; without water, it is rapidly 
disintegrated in the mouth within only a few seconds. When the ODT is placed in the oral 
cavity, saliva quickly penetrates into the tablet causing rapid disintegration.  
 
One of the most important characteristics of the ODT is its disintegration time in the 
oral cavity; however, a suitable method to access the disintegration properties described in the 
Pharmacopoeias (US, British, Japan and India) has not been developed. At present, the 
disintegration time of ODTs is measured utilizing the conventional tests (for tablets) that were 
described in the Pharmacopoeias. However, it is difficult to assess the disintegration rate for 
the ODT with these tests due to its rapid disintegration rate even in a small amount of water. 
Further, the conventional tests employ a volume of 900 mL of test solution compared to the 
volume of saliva in humans, which is less than 6 mL. Thus, the disintegration rate obtained 
from the conventional disintegration tests appears not to be reflective of the disintegration rate 
in the human mouth (Bi, Sunada et al. 1996). To overcome this problem, several new methods 
have been proposed such as; disintegration test with charge coupled device (CCD) camera, 
pressurized disintegrating test apparatus (DTA), magnetic signaled DTA, texture analyzer, 
sinker type DTA, shaker type DTA, test tube analysis, wire basket type DTA, etc. (Sharma, 
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Hardenia et al. 2009). Among them, the wire basket DTA is considered as a suitable method to 
access the disintegration properties of ODTs.  
 
Briefly, the apparatus (Figure 1.4) consisting of a glass beaker of 1000 mL capacity 
with the wire basket is positioned in the beaker with the help of a support in a way that when 
the beaker is contained 900 mL of disintegrating medium (simulated saliva fluid, pH 6.2), the 
basket has only 6 mL of it. A magnetic bead is placed at the bottom of the beaker maintaining 
at 37 ± 2
 
0
C. Disintegration time is determined at 25 and 50 rpm (Khan, Kataria et al. 2007). 
Described apparatus is very useful for predicting disintegration time similar in the mouth or 
oral cavity for fast disintegrating tablets.  
 
 
 
Figure 1.4 Wire basket type disintegrating test apparatus 
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Dissolution test 
The development of dissolution methods for ODT is comparable to approach taken for 
conventional tablets and is practically identical when ODT does not utilize taste masking. 
Commonly the drugs may have dissolution conditions as in USP monograph. Other media 
such as 0.1 N HCl (pH 1.2), pH 4.5 and pH 6.8 buffers should be used for evaluation of ODT 
in the same way as their ordinary tablet counterparts. Experience has indicated that USP II 
paddle apparatus is most suitable and common choice for dissolution test of ODTs, where a 
paddle speed of 50 rpm is commonly used. Typically the dissolution of ODTs is very fast 
when using USP monograph conditions. Hence slower paddle speeds may be utilized to obtain 
a comparative profile. Large tablets approaching or exceeding one gram and containing 
relatively dense particles may produce a mound in the dissolution vessel, which can be 
prevented by using higher paddle speeds. These two situations expand the suitable range of 
stirring to 25-75 rpm (Velmurugan and Sundar 2010). 
 
Other tests may be performed for evaluation of ODTs such as; tablet tensile strength, 
tablet porosity, evaluation of effectiveness of taste masking (in vitro and in vivo) etc. (Shukla, 
Chakraborty et al. 2009).  
 
1.2.7   Advantages and limitations of ODTs 
Some advantages and limitations of ODTs are listed in Table 1.6. 
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Table 1.6 Advantages and limitations of orally disintegrating tablets 
Advantages Limitations 
ODTs can be administered to the patients who can’t 
swallow tablets/capsules, such as elderly, stroke 
victims, bedridden patients, patients with esophageal 
problems and patients who refuse to swallow such as 
pediatric, geriatric and psychiatric patients and thus 
improve patient compliance. 
 
Increased bioavailability and proved rapid absorption 
of drugs through pregastric absorption of drugs from 
mouth, pharynx and esophagus as saliva passes down. 
 
ODTs are most convenient for disabled, bedridden 
patients, travelers and busy people, who do not always 
have access to water.  
 
Good mouth feel property of ODT helps to change the 
perception of medication. 
Some time it possesses mouth feeling. 
 
The risk of chocking or suffocation during oral 
administration of conventional formulations due to 
physical obstruction is avoided, thus providing 
improved safety. 
 
Conventional manufacturing equipment. ODT requires special packaging for 
properly stabilization and safety of 
stable product. 
Good chemical stability as conventional oral solid 
dosage forms. 
ODTs show the fragile, effervescence 
granules property. ODTs are also 
hygroscopic in nature so must be keep 
in dry place. 
ODTs provide rapid drug delivery from dosage forms.  
Cost effective.  
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Advantages Limitations 
ODTs provide advantage of liquid medication in form 
of solid preparation.  
 
Rapid onset of action.  
Rapid drug therapy intervention.  
No chewing needed.  
No water needed.   
 
(Allen and Wang 1997; Fix 1998; Chang, Guo et al. 2000; Bradoo, Shahani et al. 2001; Nagar, 
Singh et al. 2011; Indurwade, Rajyaguru et al. 2002; Bhaskaran and Narmada 2002) 
 
1.3 Schizophrenia and Clozapine 
1.3.1 Schizophrenia 
Schizophrenia is a chronic, severe, and disabling brain disorder that has affected 
people throughout history. About 1% of Americans have this illness (Regier, Narrow et al. 
1993).  Risk factors include birth in cities, birth in winter and early spring and viral infections 
in the mother during the second and third trimesters of gestation. A strong association between 
hypofrontality and negative symptoms of schizophrenia, as well as with antipsychotic 
treatment has been reported. Some studies have reported that about half of the chronic cases of 
schizophrenia show hypofrontality at rest. Studies have shown that individuals with 
schizophrenia, including those who have never been treated, have a reduced volume of gray 
matter in their brains, especially in the frontal and temporal lobes. Patients with the worst 
brain tissue loss also have the worst symptoms, including hallucinations, delusions, psychosis 
and bizarre behaviour (Sharafi 2005). 
 
There are two types of schizophrenia symptoms: positive symptoms and negative 
symptoms. Positive symptoms are psychotic behaviors not seen in healthy people. People with 
positive symptoms often “lose touch” with reality. These symptoms can come and go. 
Sometimes they are severe and at other times hardly noticeable, depending on whether the 
individual is receiving treatment. They include hallucinations, delusions, thought disorders 
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and movement disorders. Negative symptoms are associated with disruptions to normal 
emotions and behaviors. These symptoms are harder to recognize as part of the disorder and 
can be mistaken for depression or other conditions. Negative symptoms include flat affect, 
lack of pleasure in everyday life, lack of ability to begin and sustain planned activities and 
speaking little, even when forced to interact. People with negative symptoms need help with 
everyday tasks. 
 
Schizophrenia affects men and women equally. It occurs at similar rates in all ethnic 
groups around the world. Symptoms such as hallucinations and delusions usually start 
between ages 16 and 30. Men tend to experience symptoms a little earlier than women. Most 
of the time, people do not get schizophrenia after age 45 (Mueser and McGurk 2004). 
 
The risk of suicide in the general population is only about 1%. But people with 
schizophrenia are at a much greater risk of suicide. Approximately 30% to 40% of people with 
schizophrenia attempt suicide at some point in their lifetime. About 10% will actually die by 
suicide. In fact, suicide is the most common cause of premature death among people with 
schizophrenia. And the suicide rate may be even higher for people with schizoaffective 
disorder. Although suicidal behavior is difficult to predict, research scientists have found 
several factors that can increase the risk of suicide in people with schizophrenia.  
 
1.3.2 Clozapine 
 Clozapine, an atypical antipsychotic agent, is commonly prescribed for the 
management and symptomatic relief from the symptoms of severe schizophrenia. Clozapine is 
a selective monoaminergic antagonist with high affinity for the serotonin Type 2 (5HT2), 
dopamine  Type 2 (D2), 1 and 2 adrenergic and H1 histaminergic receptors and can also be 
used for treating various dopamine-mediated behaviours (Ahmed, Li et al. 2010).  
 
Properties of Clozapine: 
Formula: C18H19CIN4 
Molecular weight: 326.82 g/mol 
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Melting point: 183-184
0 
Solubility in water: 0.189 mg/mL (20 
0
C) (slightly soluble in water) 
(http://en.wikipedia.org/wiki/Clozapine) 
 
pKa: pKa1 3.70 pKa2 7.60 
Log P: Partition coefficient (octanol/water): 0.4 (pH 2), 600 (pH 7), 1000 (pH 7.4), 1500 (pH 
8) (http://www/drugfuture.com/chemdata/clozapine.html) 
 
 Clozapine is the prototype of atypical antipsychotic drugs that are used to treat 
patients with schizophrenia who are unresponsive or intolerant to typical antipsychotics. It is 
effective in treating the positive and negative symptoms of schizophrenia. Clozapine is more 
effective in schizophrenia than older antipsychotics. It may also help to reduce relapses, 
suicide and the need for hospitalization (Sharafi 2005). Clozapine reduces suicidal behaviour 
in patients with schizophrenia. Clozapine has been shown to have a substantial effect on 
attempted suicide and completed suicide (Novakovic and Sher 2012). Clozapine has a number 
of characteristics that make it unique. It appears to be more effective than conventional 
antipsychotics for schizophrenia patients who are severely psychotic and poorly responsive to 
the mechanism of action of conventional antipsychotic drugs. Another important characteristic 
of clozapine is its spectrum of antipsychotic activity (Kane, Honifeld et al. 1988). Clozapine 
has been found superior for both positive and negative symptoms than any other atypical 
antipsychotics (Preskorn, Burke et al. 1993; Breier, Buchanan et al. 1994). 
 
After oral administration, clozapine is rapidly absorbed, but there is extensive                    
first-pass metabolism and only 27-50% of the dose reaches the systemic circulation 
unchanged. So the relative bioavailability of clozapine is very low. Clozapine is approximately 
95% bound to plasma proteins. Its plasma concentration declines in the biphasic manner and 
its elimination half-life ranges from 6 to 33 hrs. About 50% of a dose is excreted in urine and 
30% in the faeces (Naheed and Green 2001).  
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1.4 Hypothesis of the thesis 
The hypothesis that the drug (clozapine) is dissolved in the liquid vehicle (PG) may be 
chiefly responsible for its enhanced dissolution rate. According to the LS hypothesis, the 
phenomena of absorption and adsorption occur when clozapine (dissolved in PG) is 
incorporated into a carrier and coating system.  
 
1.5 Objectives of the thesis 
The principle focus of this project is to formulate LS compacts of poorly water soluble 
drug, clozapine to enhance its dissolution rate. For this purpose, the LS powder blends and 
tablets of clozapine were prepared. The specific aims of the project are to: 
 
 Investigate the influence of the type of coating material, 
 
 Investigate the influence of the excipient ratio (R), 
 
 Investigate the influence of the liquid load factor (Lf)  
 
on the flow properties of LS powder blends and on the in vitro release of clozapine from LS 
tablets. 
 
 Formulate OD-LSTs of clozapine to enhance its dissolution rate.  
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2.1 Abstract 
The objective of this research was to develop a liquisolid (LS) formulation of 
clozapine with improved dissolution properties and evaluate its robustness to excipient 
modifications as well as its stability. Propylene glycol (PG), microcrystalline cellulose (MCC) 
and sodium starch glycolate (SSG) were employed as non-volatile liquid vehicle, carrier 
material and disintegrant respectively for preparing LS compacts. Colloidal silicon dioxide 
(CSD), calcium silicate (CS) and magnesium aluminometasilicate (MAMS) were selected as 
coating materials. Complete characterisation of the blends and tablets was performed. The 
drug release rates of LS compacts were distinctly higher as compared to regular tablets. The 
specific surface areas of coating materials had an effect on the flow properties of the blends 
and the particle sizes of coating materials affected the dissolution rate. The powder to 
excipient ratio was an important parameter for LS systems and had to be larger than 20 to 
obtain enhanced drug release. The selected formulation demonstrated stability for a period of 
at least 12 months. The LS technique was an effective approach to prepare clozapine tablets 
with enhanced dissolution properties. 
 
Keywords: Liquisolid, clozapine, formulation, tablet, excipients, dissolution, stability 
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2.2 Introduction 
Dissolved state is a requirement for absorption drugs through gastrointestinal tract. In 
the case of poorly soluble drugs, dissolution is the rate-limiting step in absorption process 
(Wong et al., 2006). Generally, compounds with aqueous solubility lower than 100 μg/mL 
show dissolution-limited absorption (Hörter and Dressman, 2001) and erratic and incomplete 
absorption after oral administration (Wong et al., 2006). Advancements in the fields of 
biotechnology and drug discovery have led to the discovery of increasingly large number of 
active molecules. However, the intestinal absorption of 40% of all newly developed drugs is 
limited by their aqueous solubility, leading to ineffective absorption and therapeutic failure 
(Rong, 2008). 
 
Various techniques have been employed to formulate oral drug delivery systems that 
would enhance the dissolution profile and in turn, the absorption efficiency of poorly water 
soluble drugs (Shinde, 2007). These techniques take advantage of the increased dissolution 
rate resulting from the addition of a solubilizing agent, particle size reduction or the drug 
being in already dissolved or amorphous state:  Solid dispersions (Kapsi and Ayres, 2001; 
Shah et al., 2007; Rane et al., 2007; Vanshiv et al., 2009), micronization (Li et al., 2007; 
Nighute and Bhise, 2009), use of mesoporous silica carriers (Ahuja and Pathak, 2009), ball 
milling technique (Sonoda et al., 2008), use of complexing agents (El-Zein et al., 1998; Pravin 
and Nagarsenker, 2004; Ghorab et al., 2004; Gowrishankar et al., 2007), crystal engineering 
(Blagden et al., 2007), solubilization by surfactants (Nazzal et al., 2002; Patil and Paradkar, 
2006) and LS technique developed by Spireas (Spireas and Bolton, 1999; Spireas, 2002).  
 
LS technique was previously reported to improve the dissolution rate of poorly water 
soluble drugs (Fahmy and Kassem, 2008). When properly formulated, LS powder blends 
possess acceptable flowability and compressibility properties. They are prepared by simple 
blending with selected powder excipients referred to as the carriers and the coating materials.  
 
This technique was successfully applied for low dose poorly water soluble drugs. Drug 
can be present in a completely or partially dissolved state in the LS formulation. The LS 
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formulation can then facilitate the release of this drug by two mechanisms: (1) Already 
dissolved drug only need to diffuse out of the formulation and (2) the liquid component of the 
formulation act as a solubilizing aid to facilitate the wetting and dissolution of undissolved 
particles. Since dissolution of poorly water soluble drugs is often the rate limiting step in 
gastrointestinal absorption, better bioavailability can be achieved when they are formulated 
using a LS system.  
 
 LS technique is a powdered solution technology that can be used to formulate liquid 
medication (Tiong and Elkordy, 2009). LS system is defined as dry, non-adherent, free 
flowing and compressible powder mixtures converted from liquid drugs, drug suspensions or 
drug solutions in non-volatile solvents with selected carriers and coating materials 
(Javadzadeh et al., 2007). The liquid portion, which can be a liquid drug, a drug suspension or 
a drug solution in suitable non-volatile liquid vehicles, is incorporated into the porous carrier 
material. Once the carrier is saturated with liquid, a liquid layer is formed on the particle 
surface which is rapidly adsorbed by the fine coating particles. Thus, an apparently dry, free 
flowing and compressible powder is obtained. Since non-volatile solvents are used to prepare 
the drug solution or suspension, the liquid is not evaporated and the drug is carried in a liquid 
system and is dispersed throughout the final product. The drug in the solid dosage form is held 
within the powder substrate in a solubilized or finely dispersed form which is the main reason 
for the enhanced dissolution rate. The quantity of drug available for dissolution is increased 
and hence show enhanced drug release characteristics and improved oral bioavailability 
(Manogar et al., 2011). Besides drug release enhancement, the LS approach is a promising 
technique because of the simple manufacturing process, low production costs and the 
possibility of industrial manufacture due to the good flow and compaction properties of the LS 
formulations. 
 
Clozapine is a poorly water soluble antipsychotic drug used for treatment-resistance 
schizophrenia. Extent and rate of absorption of clozapine are critical and therefore it could 
benefit from the LS technology. The objective of this research was to develop a LS 
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formulation of clozapine with improved dissolution properties and evaluate its robustness to 
excipient modifications as well as its stability. 
 
Specifically, this project investigated the influence of the type of coating material, 
powder excipient ratio (R value) and liquid load factor (Lf) on the flow properties of LS 
powder blends and on the in vitro release of clozapine from LS tablets; a stability study was 
also performed. 
  
2.3 Materials and methods 
2.3.1   Materials 
Clozapine was provided by AK Scientific Inc. (USA). Propylene glycol (PG, Medisca, 
USA), microcrystalline cellulose (MCC, Avicel PH102, FMC, USA), colloidal silicon dioxide 
(CSD, Aerosil 200, Degussa AG, Germany), calcium silicate (CS, 200 mesh, Sigma-Aldrich, 
USA), magnesium aluminometasilicate (MAMS, Neusilin US2, Fuji, Japan) and sodium 
starch glycolate (SSG, Explotab, Mendell, USA) were purchased from major suppliers. All 
other reagents were of analytical grade and used without further purification. 
 
2.3.2   Methods 
2.3.2.1     Use of a mathematical model to design LS compacts 
The formulation design of LS systems was done in accordance with a mathematical 
model proposed by Javadzadeh (2007). In this study, PG was used as a liquid vehicle, MCC 
was used as carrier material and three different coating materials were used.  
 
The concentration of the drug in solvent was kept constant in all formulations. 
According to this model, the carrier and coating powder materials can retain only certain 
amounts of liquid while maintaining acceptable flowability and compressibility.  
 
Firstly, the excipient ratio R of the powder is defined as, 
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R = Q / q 
 
Where R is the ratio of the weight of carrier (Q) and coating (q) materials present in the 
formulation.  
 
Secondly, the liquid load factor (Lf) is defined as the ratio of the weight of liquid 
medication (W) to the weight of the carrier material (Q) in the system. This ratio can be 
correlated with the flow and the compression properties of a given LS system.  Lf is defined 
as, 
 
Lf = W / Q 
 
2.3.2.2     Preparation of LS powder blends and tablets of clozapine 
Calculated quantities of clozapine and PG were accurately weighed and mixed together 
until a homogeneous drug solution was obtained. The resulting liquid medication was 
incorporated into calculated quantities of carrier and coating materials. The mixing process 
was carried out in three steps. In the first, the system was blended in a mortar using pestle at a 
mixing rate of one rotation per second for one minute in order to evenly distribute the liquid 
medication in the powder. In the second, the liquid/powder admixture was evenly spread as a 
uniform layer on the surface of a mortar and left standing for 5 min to allow the drug solution 
to be absorbed inside powder particles. In the third, the powder was scraped off the mortar 
surface using a spatula. The final mixture was compressed into tablets by using a manual 
hydraulic press (15 ton press, Specac, England) equipped with round flat-faced tooling 
(diameter 12.6 mm) using a compression force of 25 kN. 
 
Preliminary experiments were conducted to identify adequate LS composition (LS-1, 
Table 2.1) using common excipients. This system was composed of PG as a non-volatile 
liquid vehicle, MCC as a carrier, CSD as a coating material and SSG as a disintegrant. The 
robustness of this formulation to excipients modifications was evaluated.  
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Firstly,  LS formulations of clozapine (LS-1, LS-2 and LS-3, Table 2.1) with different 
R values (10.0, 20.9 and 30.2) were prepared to investigate the influence of the excipient ratio 
on the flow properties of LS powder blends and on the in vitro release of clozapine from LS 
tablets.  
 
Secondly, LS formulations of clozapine (LS-1, LS-4 and LS-5, Table 2.1) were 
prepared to investigate the influence of the type of coating material on the flow properties of 
LS powder blends and on the in vitro release of clozapine from LS tablets. The particle size 
and specific surface area of the coating materials may affect the flow properties and the drug 
release. For this purpose, CSD, CS and MAMS were selected as coating materials. The 
particle size (d50) of CSD, CS and MAMS were 12 µm, 74 µm and 100 µm and the specific 
surface area of these materials were 200 m2/g (Hentzschel 2011), 142 m2/g (Hentzschel et al., 
2011) and 339 m
2
/g (Shah et al., 2012), respectively. 
 
Thirdly, LS formulations of clozapine (LS-1, LS-6, LS-7 and LS-8, Table 2.1) with 
different Lf values (0.427, 0.382, 0.345 and 0.315) were prepared using PG as a non-volatile 
liquid vehicle to investigate the influence of the liquid load factor on the flow properties of LS 
powder blends and on the in vitro release of clozapine from LS tablets.  
 
Each system (LS-1 to LS-8, Table 2.1) was containing 100 mg of clozapine and 65 mg 
of PG. The detailed formulation characteristics of these systems are shown in Table 2.1. 
 
2.3.2.3     Preparation of conventional tablets of clozapine 
Conventional tablets of clozapine were prepared for comparison purposes. These 
tablets were produced by direct compression using a manual hydraulic press (15 ton press, 
Specac, England) equipped with round flat-faced tooling (diameter 12.6 mm) using a 
compression force of 25 kN. Each tablet contained clozapine (100 mg), MCC (405 mg), CSD 
(17 mg) and SSG (28 mg).  
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Table 2.1 Formulation design of clozapine liquisolid tablets 
System Lf R Clozapine (mg) PG (mg)     MCC (mg) CSD (mg) MAMS (mg)  CS (mg) SSG (mg) Total (mg) 
LS-1 0.427 20.9 100.0 65.0 386.5 18.5 - - 30.0 600 
LS-2 0.448 10.0 100.0 65.0 368.0 37.0 - - 30.0 600 
LS-3 0.421 30.2 100.0 65.0 392.0 13.0 - - 30.0 600 
LS-4 0.427 20.9 100.0 65.0 386.5 - 18.5 - 30.0 600 
LS-5 0.427 20.9 100.0 65.0 386.5 - - 18.5 30.0 600 
LS-6 0.382 21.6 100.0 65.0 432.0 20.0 - - 33.0 650 
LS-7 0.345 22.3 100.0 65.0 478.5 21.5 - - 35.0 700 
LS-8 0.315 22.8 100.0 65.0 524.0 23.0 - - 38.0 750 
 
 
 
 
 
 
 
 
 
 
78 
 
2.3.2.4     Flow properties of LS systems 
The tapping method was used to investigate the flow properties of prepared LS powder 
blends. Bulk density measurements were carried by placing fixed weight of powder in 
graduated cylinder and volume occupied was measured and initial bulk density was calculated. 
20 grams of the prepared powder blends were placed in a 50 mL cylinder. The cylinder was 
then tapped 1000 times at a constant velocity. The tapped density was determined on a tapped 
volume determination apparatus (Vanderkamp, Vankel Ind., New Jersey, USA). Each analysis 
was carried out in triplicate.  
 
2.3.2.5    Weight variation, hardness, friability and content uniformity tests 
The prepared tablets were evaluated by carrying out tests for weight variation, 
hardness, friability and drug content uniformity. For estimating weight variation, 20 tablets 
were taken randomly from each tablet formulation and weighed individually. The average 
weight of all tablets and percentage deviation from the mean for each tablet were determined.  
 
 The hardness of formulated tablets was assessed using a hardness tester (PTB 301, 
Pharma Test AG, Hainburg, Germany) and the mean hardness of three tablets was determined. 
The friability was determined on ten tablets using a friability tester (PTF II, Pharma Test AG, 
Hainburg, Germany) and the percentage loss in weight was calculated.  
 
For drug content uniformity test, ten tablets were crushed individually and powder 
equivalent to 100 mg of clozapine was dissolved in 100 mL of methanol. The solution was 
then passed through a 0.45 µm nylon filter and analyzed using UV spectrophotometer (WPA, 
Biochrom Ltd., Cambridge, England) at 290 nm after sufficient dilution with pH 4.5 acetate 
buffer.  
 
2.3.2.6     In vitro dissolution studies 
The USP apparatus II (paddle method) (DTB 678 equipment with thermostatic bath 
and circulation pump VTC-100, Logan Instruments Corporation, New Jersey, USA) was used 
for all the in vitro dissolution studies. In this method, acetate buffer having the pH of 4.5 was 
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used as dissolution media. The rate of stirring was 50 rpm. The dosage forms were placed in 
900 mL of pH 4.5 acetate buffer maintained at 37 ± 0.5 ⁰C. At appropriate intervals (5, 10, 15, 
20, 30 and 45 min), 5 mL of the samples were taken. The dissolution media was then replaced 
by 5 mL of fresh dissolution fluid to maintain a constant volume. After proper dilution, the 
samples were analyzed at 290 nm spectrophotometrically (WPA, Biochrom Ltd., Cambridge, 
England). The mean of three determinations was used to calculate the drug release from each 
of the formulations. 
 
2.3.2.7     Stability study 
 The effect of aging on the hardness and dissolution of LS tablets (LS-1) was 
determined by storing the tablets at 22 
0
C for up to 12 months. After that, the samples were 
tested for their dissolution profiles and hardnesses at the conditions that have been used with 
freshly prepared tablets. The results were compared with the freshly tested tablets.  
 
2.4 Results and discussion 
2.4.1 Flow properties 
 Good flow properties are critical for larger scale production of tablet dosage forms. To 
evaluate the flow properties of the prepared LS powder blends, Carr’s index was calculated 
from the bulk and tapped densities of the blends. According to the USP, powders are 
considered to have passable flow properties if they have a Carr’s index value of less than 25% 
(USP36-NF31, 2013).  
 
R value is an important formulation parameter for LS systems that may be optimized. 
The R values of LS-1, LS-2 and LS-3 were 20.9, 10.0 and 30.2 respectively. As shown in 
Table 2.2, LS-1 and LS-3 had fair flow properties because the formulations were containing 
high quantities of MCC and low quantities of colloidal silica. LS-2 exhibited passable flow 
properties because the formulation was containing high amounts of colloidal silica. 
 
As shown in Table 2.2 the LS-1 had fair and LS-4 had good flow properties according 
to the Carr’s index, but LS-5 exhibited poor flow properties. CS with its petaloid crystal 
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structure and large micropores exhibited the smallest specific surface area which is lower than 
that of CSD with its loose particle aggregates. MAMS which is prepared by spray drying 
resulting in spherically shaped, porous, ultralight granules showed an almost 1.5 fold larger 
specific surface area than CSD (Hentzschel, 2011). LS-5 powder system prepared using CS 
showed poor flow properties, because CS has the lowest specific surface area in comparison to 
CSD and MAMS. This study showed that the nature of the coating agent and most likely its 
specific surface area has an effect on the flow properties of LS powders.   
 
As shown in Table 2.2, the LS-1 and LS-6 had fair and LS-7 and LS-8 had good flow 
properties according to the Carr’s index. It was found that there is a relationship between Lf 
and the flow properties of LS powder blends. The LS systems with low Lf values have better 
flow properties. This can be explained by the fact that, the LS systems with high Lf values 
contain high amounts of liquid and low quantities of powder excipient. In contrast, the LS 
systems with low Lf values contain high amounts of carrier material (MCC) and low quantities 
of liquid.  
 
Table 2.2 Flow properties of liquisolid powder blends 
System Carr’s index (%) Type of flow 
LS-1 19.8 ± 0.3 Fair 
LS-2 24.6 ± 0.3 Passable 
LS-3 16.5 ± 0.7 Fair 
LS-4 11.5 ± 0.4 Good 
LS-5 30.0 ± 0.4 Poor 
LS-6 17.6 ± 0.7 Fair 
LS-7 15.2 ± 0.8 Good 
LS-8 15.5 ± 0.5 Good 
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2.4.2 Weight variation, friability, hardness and content uniformity tests 
The results of weight variation, friability, hardness and drug content are represented in 
Table 2.3. Average weight of LS tablets ranged from 598 ± 2 mg to 748 ± 2 mg.  
 
All the clozapine LS tablets had acceptable friability as none of the tested formulae had 
percentage loss in tablet’s weights that exceed 1%, also no tablet was cracked, split or broken 
in either formula. Since all prepared tablets met the standard friability criteria, they are 
expected to show acceptable durability and withstand abrasion in handling, packing and 
shipment.  
 
In general, formulation should be directed at optimizing tablet hardness without 
applying excessive compression force, while at the same time assuring rapid tablet 
disintegration and drug dissolution. In other words, tablets should be sufficiently hard to resist 
breaking during normal handling and yet soft enough to disintegrate properly after 
swallowing. The mean hardness of each LS tablet was determined and is presented in Table 
2.3 providing that all the LS tablets had acceptable hardness. All LS formulations have shown 
lower hardness compared with that of conventional formula (DCT). This was due to the 
presence of the liquid in the LS formulations that hinder the formation of the interparticle 
bonds (H-bonds in case of MCC) which are the main reason for the higher specific hardness 
obtained in DCT.  
 
It was found that there is a relationship between R value and the hardness of the 
tablets. The R value was inversely proportional to the hardness of the tablets i.e., when the R 
value increases, the hardness of the tablet will decrease. This was obvious from the following 
results. LS-2 had R value equal to 10.0 and the mean hardness was 171 N. LS-3 had R value 
equal to 30.2 and the mean hardness was 104 N. This can be explained by that, increasing R 
value increases the amount of carrier powder (MCC) used which is a highly porous material 
and the amount of coating material (colloidal silica) will decrease and this subsequently leads 
to decreased hardness of the tablets.  
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 It was found that there is a relationship between Lf and the hardness of the tablets in 
the LS formulation having approximately the same R value. The Lf was inversely proportional 
to the hardness of the tablets i.e., when the Lf increases, the hardness of the tablets will 
decrease. This was obvious from the following results. LS-1, LS-6, LS-7 and LS-8 were 
having Lf 0.427, 0.382, 0.345 and 0.315 and the mean hardness of them was 120, 123, 167 and 
194 N, respectively. This can be explained by that, increasing Lf of the formulation increases 
the amount of solvent used and decreases the amount of the powder excipient and this 
subsequently decreases the hardness of the tablets. 
 
It was clear from Table 2.3 that all the investigated clozapine LS tablets complied with 
the pharmacopoeial requirements as regard their content uniformity which was found to lie 
within the range 90-110%.  
 
Table 2.3 Evaluation of clozapine liquisolid tablets 
LS system Hardness (N) 
Friability 
Weight variation 
(mg) 
Drug content 
(%) 
Fines 
(%) 
No. of broken 
tablets 
LS-1 120 ± 2 0.25 None 599 ± 2 100 ± 2 
LS-2 171 ± 5 0.12 None 598 ± 2 98 ± 3 
LS-3 104 ± 8 0.34 None 600 ± 2 98 ± 5 
LS-4 124 ± 4 0.23 None 599 ± 1 100 ± 4 
LS-5 95 ± 7 0.14 None 599 ± 2 97 ± 5 
LS-6 123 ± 7 0.28 None 649 ± 4 99 ± 3 
LS-7 167 ± 8 0.18 None 699 ± 3 96 ± 5 
LS-8 194 ± 10 0.45 None 748 ± 2 99 ± 3 
DCT 216 ± 6 0.45 None 549 ± 2 101 ± 3 
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2.4.3  In vitro dissolution studies 
The dissolution profiles of clozapine LS tablets (LS-1) and directly compressed tablets 
(DCT) in pH 4.5 acetate buffer are shown in Figure 2.1. Dissolution rates of LS tablets were 
compared with DCT. LS formulation showed greater release than DCT formulation. The 
percentages of drug released from LS-1 and DCT after 5 min were 99.6% and 32.5% 
respectively at pH 4.5 acetate buffer. This showed that the LS compacts produced faster 
dissolution rate in comparison with DCT. 
 
The enhanced dissolution rates of LS tablets compared to DCT may be attributed to the 
fact that, the drug is already in solution in PG, while at the same time, it is carried by the 
powder particles (MCC and CSD). When the drug within the LS system is completely 
dissolved in the liquid vehicle, it is located in the powder substrate still in a solubilized state. 
Therefore they show improved release rates.  
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                Figure 2.1 Dissolution profiles of clozapine from liquisolid tablets and  
                             directly compressed tablets (means ± SD; n=3) 
 
The R value is an important parameter which is the ratio between the weights of the 
carrier and the coating material that may be optimized. An increase in the R value results in an 
enhanced release rate, if MCC and colloidal silica are used as carrier and coating materials, 
respectively. LS compacts with high R values contain high amounts of MCC, low quantities of 
CSD and low liquid to powder ratios. This is associated with enhanced wicking, disintegration 
and thus, enhanced drug release. In contrast, if high amounts of colloidal silica are used, which 
means that the R value is low, the LS compact is overloaded with liquid formulation due to a 
high Lf. In such cases, even though drug diffusion out of the primary particles may be rapid, 
oversaturation might occur resulting in local precipitation or recrystallization of the drug and 
thus decreased release rates (Javadzadeh et al., 2007).  
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As shown in Figure 2.2, the LS formulations that had R values of 20.9 (LS-1) and 30.2 
(LS-3) exhibited similar drug release profiles with small variations while the LS formulation 
that had low R value of 10.0 (LS-2) showed lower drug release.  This study confirmed that the 
R value is an important parameter for LS systems and must be minimum 20 to obtain 
enhanced drug release (Spireas  et al., 1999). 
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           Figure 2.2 Dissolution profiles of clozapine from liquisolid tablets that  
              had different R values (means ± SD; n=3) 
 
The dissolution profiles of clozapine from LS tablets containing different coating 
materials in pH 4.5 acetate buffer are shown in Figure 2.3. The dissolution test results showed 
that LS-1 containing CSD had the highest drug release compared with LS-4 containing MAMS 
and LS-5 containing CS. The particle size of CS (74 µm) is smaller than that of MAMS (100 
µm), but is much higher than that of CSD (12 µm). Therefore the drug release from LS-5 was 
higher than that of LS-4, but was lower than that of LS-1 as expected. This study confirmed 
that the particle size of the coating materials has an effect on the release of clozapine from LS 
tablets and CSD is the best suitable coating material for preparing LS compacts of clozapine.  
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Figure 2.3 Dissolution profiles of clozapine from liquisolid tablets   
containing different coating materials (means ± SD; n=3) 
 
 
The dissolution profiles of clozapine from LS tablets with different Lf values in pH 4.5 
acetate buffer are shown in Figure 2.4. The LS formulations with different Lf values exhibited 
similar drug release profiles with small variations. This study showed that the Lf values did not 
cause important differences on the drug release from LS tablets.  
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  Figure 2.4 Dissolution profiles of clozapine from liquisolid tablets  
       that had different Lf values (means ± SD; n=3) 
 
2.4.4 Stability study 
 The effect of aging on the hardness and dissolution rate of LS tablets (LS-1) was 
determined by storing the tablets at 22 
0
C for up to 12 months. The dissolution rate and 
hardness were measured for the LS tablets at the end of 3, 6 and 12 months. The results 
showed that storage at 22 
0
C neither had an effect on the hardness (Table 2.4) nor on the 
release profiles (Figure 2.5) of LS compacts. These results indicate that in the case of 
clozapine the LS technology is a promising technique to enhance the release rate without 
having any stability issues.  
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Table 2.4 Hardness results of clozapine liquisolid tablets (fresh and aged) 
LS system 
Hardness (N) 
(fresh) 
Hardness (N) 
(aged, 3 months) 
Hardness (N) 
(aged, 6 months) 
Hardness (N) 
(aged, 12 months) 
LS-1 120 ± 2 110 ± 5 116 ± 6 114 ± 5 
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      Figure 2.5 Dissolution profiles of clozapine from liquisolid tablets                                                   
(fresh and aged) (means ± SD; n=3) 
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2.5 Conclusion 
LS technique has been used successfully to produce a tablet dosage form of clozapine 
with faster dissolution rate than the regular tablet. Various trials were characterized based the 
blend and tablet parameters which showed the LS formulation containing MCC, CSD and 
SSG with clozapine dissolved in PG as a robust formula with required parameters. It showed 
significant increase in dissolution as compared DCT. It was found that there is a relationship 
between the carrier to coating material ratio (R value) and the in vitro release of clozapine 
from LS tablets. The R value was directly proportional to the in vitro release of clozapine from 
LS formulations. This study showed that the specific surface area of coating materials has an 
effect on the flow properties of LS powder blends and the particle size of coating materials 
affects the drug release from LS tablets. It was found that the liquid load factor (Lf) has an 
effect on the flow properties of LS powder blends but had no significant effect on the drug 
release from LS tablets. It was observed that aging had no significant effect on the hardness 
and dissolution profile of clozapine LS compacts. Although, better flow properties could be 
obtained using MAMS when compared to CSD, this former material resulted in slower 
dissolution rate. The LS-1 formulation was therefore considered optimal as it provided 
improve dissolution properties while being stable and robust to excipients modifications. 
 
In conclusion, this study showed that LS technique could be a promising strategy in 
improving dissolution of poorly water soluble drugs such as clozapine and formulating 
immediate release dosage forms.   
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Chapter three 
 
3 Formulation development and dissolution rate 
enhancement of clozapine by orally disintegrating 
liquisolid systems 
 
3.1 Overview 
Patients, particularly pediatric and geriatric patients have difficulty in swallowing solid 
dosage forms. These patients are unwilling to take these solid preparations due to fear of 
choking. In order to assist these patients, several mouth dissolving drug delivery systems have 
been developed. ODTs dissolve rapidly in the saliva without the need for water and release the 
drug. Some drugs are absorbed from the oral cavity as the saliva passes down into stomach. In 
such cases, bioavailability of drug is significantly greater than those observed conventional 
tablet dosage forms (Reddy, Ahad et al. 2011). ODTs can be preferred for dosage forms for 
patients suffering from schizophrenia because they can be taken without water intake and 
disintegrate immediately upon contacting the tongue or buccal cavity, thereby improving 
patient compliance (Ahmed, Li et al. 2010).  
 
Clozapine is an antipsychotic drug used to alleviate the symptoms and signs of 
schizophrenia, hallucinations, delusions and unusual behavior. The main criteria for ODTs is 
to disintegrate/dissolve rapidly in oral cavity with saliva without need of water and should 
have pleasant mouth feel (Reddy, Ahad et al. 2011). Clozapine is subject to first pass 
metabolism, resulting in an absolute bioavailability of 50 to 60% which is very low (Quitkin, 
Adams et al. 1998). It is poorly water soluble drug and rate of absorption of clozapine is often 
controlled by its solubility and dissolution rate. Some schizophrenic patients hide a 
conventional tablet under their tongue to avoid its daily dose of atypical antipsychotic. Also 
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schizophrenic patients with dsyphagia are not able to swallow conventional tablets 
(Shankarrao, Mahadeo et al. 2010). ODTs are a perfect fit for all these patients.  
 
LS technology promotes the dissolution rate of poorly water soluble drugs to a greater 
extent. LS compacts of poorly water soluble drugs containing a drug molecularly dispersed in 
a liquid vehicle show enhanced drug dissolution. Accordingly, the improved drug dissolution 
may result in higher drug absorption and thus, improved oral bioavailability (Basalious,          
El-Sebaie et al. 2013). This technique was successfully applied for low dose poorly water 
soluble drugs. Drug can be present in a completely or partially dissolved state in the LS 
formulation. The LS formulation can then facilitate the release of this drug by two 
mechanisms: (1) Already dissolved drug only need to diffuse out of the formulation and (2) 
the liquid component of the formulation act as a solubilizing aid to facilitate the wetting and 
dissolution of undissolved particles. Since dissolution of poorly water soluble drugs is often 
the rate limiting step in gastrointestinal absorption, better bioavailability can be achieved when 
they are formulated using a LS system.  
 
  Literature lacks any data about application of LS technique for development of 
clozapine orally disintegrating LS tablets (OD-LST) useful for management of schizophrenia 
crisis. The developed clozapine OD-LSTs with enhanced dissolution rate may hasten the 
absorption of clozapine and avoid its hepatic first pass metabolism through the partial 
absorption from buccal mucosa and esophagus. Thus, in this study, it was proposed to 
formulate an oral delivery system containing clozapine, in the formulation of OD-LST to 
enhance its dissolution rates.  
 
3.2 Literature review on orally disintegrating liquisolid tablets (OD-LSTs) 
 Aceclofenac is a NSAID, showing effective anti-inflammatory and analgesic properties 
mainly used in osteroarthritis, rheumatoid arthritis and anklysoling spondylitis (Legrand 
2004). Aceclofenac being poorly soluble in water its rate of oral absorption is often controlled 
by the dissolution rate in the GIT (Amidon, Lennernäs et al. 1995). In the present study, LS 
compacts of aceclofenac were prepared by dispersing drug in various non-volatile solvents 
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(PEG 400, PG, polysorbate 80). MCC was added as a carrier. CCS, SSG and CP were used as 
superdisintegrants. Magnesium stearate and silica were mixed with granules as a glidant and 
lubricant respectively. Finally granules were compressed using manual tableting machine. 
Orodispersible LS compacts prepared with polysorbate 80 enhance the dissolution rate of 
aceclofenac to a greater extent. Compacts with SSG added intragranularly and CP 
extragranularly showed highest dissolution rate (Yadav, Shete et al. 2005).  
 
 Felodipine is a calcium channel blocker used as antihypertensive and antianginal drug. 
Felodipine has poor water solubility and hence poor dissolution and bioavailability after oral 
administration (Acholu, Yajaman et al. 2013). Felodipine was proposed as a candidate drug in 
emergency and treatment of hypertensive crisis. Literature lacks any data about the application 
of LS technique for development of felodipine LS orodispersible tablet (FLODT) useful for 
management of hypertension crisis. Thus, in the present study, orodispersible LS compacts of 
felodipine were prepared using PEG 400 and PG as non-volatile liquid vehicles, MCC and 
silicified MCC as carrier materials, silica as a coating material, CP as a superdisintegrant and 
aspartame as a sweetening agent. The optimized FLODT formulation showed a significant 
increase in dissolution rate compared to felodipine solution in PEG filled in soft gelatin 
capsule in 0.5% sodium lauryl sulphate (SLS) solution. The in vivo PK study suggests that the 
optimized FLODT developed in this work may be useful for management hypertensive crisis 
due to enhanced dissolution and rapid absorption of felodipine through the buccal mucosa 
(Basalious, El-Sebaie et al. 2013).  
 
3.3 Materials and methods 
3.3.1  Materials 
Clozapine was provided by AK Scientific Inc. (USA). Propylene glycol (PG, Medisca, 
USA), microcrystalline cellulose (MCC, Avicel PH102, FMC, USA), colloidal silicon dioxide 
(CSD, Aerosil 200, Degussa AG, Germany), mannitol (Pearlitol
 
200 SD, Roquette, France), 
crospovidone (CP, Polyplasdone XL-10, ISP, USA), lactose monohydrate (Galenova, Canada) 
and sodium saccharin (SS, Giroux Lab., Canada) were purchased from major suppliers. All 
other reagents were of analytical grade and used without further purification. 
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3.3.2 Methods 
3.3.2.1     Preparation of OD-LSTs of clozapine 
Calculated quantities of clozapine and PG were accurately weighed and mixed together 
until a homogeneous, fine dispersion was obtained. The resulting liquid medication was 
incorporated into calculated quantities of carrier and coating materials. The mixing process 
was carried out in three steps. In the first, the system was blended at a mixing rate of one 
rotation per second for one minute in order to evenly distribute liquid medication in the 
powder. In the second, the liquid/powder admixture was evenly spread as a uniform layer on 
the surface of a mortar and left standing for 5 min to allow the drug solution to be absorbed 
inside powder particles. In the third, the powder was scraped off the mortar surface using a 
spatula. The final mixture was compressed into tablets by using a manual hydraulic press (15 
ton press, Specac, England) equipped with round flat-faced tooling (diameter 12.6 mm) using 
a compression force of 25 kN after addition of sweetening agent and superdisintegrant. The 
ODTs were prepared using direct compression technique. The simplicity and cost 
effectiveness of the direct compression technique have positioned direct compression as an 
alternative to the other techniques such as spray-drying, melt granulation, freeze-drying etc.  
 
Preliminary experiments were conducted to identify adequate OD-LST composition 
(OD-LST, Table 3.1) using common excipients. This system was composed of PG as a                     
non-volatile liquid vehicle, MCC as a carrier material, mannitol as a carrier material and 
sweetening agent, CSD as a coating material, CP as a superdisintegrant and SS as a 
sweetening agent.  
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Table 3.1 Formulation design of clozapine orally disintegrating  
liquisolid tablets 
System OD-LST 
Lf
*
 0.210 
R
**
 20.0 
Clozapine (mg) 25.0 
PG (mg) 15.0 
MCC (mg) 40.0 
Mannitol (mg) 150.0 
CSD (mg) 9.5 
CP (mg) 58.0 
SS (mg) 2.5 
Total (mg) 300 
 
*Lf : Liquid load factor 
**R : The carrier : coating ratio of the powder system 
 
3.3.2.2     Preparation of conventional ODTs of clozapine 
Conventional ODTs (DC-ODT) of clozapine were prepared for comparison purposes 
These tablets were produced by direct compression using a manual hydraulic press (15 ton 
press, Specac, England) equipped with round flat-faced tooling (diameter 12.6 mm) using a 
compression force of 25 kN. Each tablet contained clozapine (25 mg), MCC (70 mg), 
mannitol (90 mg), lactose monohydrate (27 mg), CSD (8 mg) and CP (55 mg). 
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3.3.2.3     Weight variation, hardness, friability, content uniformity, 
disintegration time, wetting time and water absorption capacity 
tests  
The prepared OD-LSTs were evaluated by carrying out tests for weight variation, 
hardness, friability, content uniformity, disintegration time, wetting time and water absorption 
percent. For estimating weight variation, 20 tablets were taken randomly from each tablet 
formulation and weighed individually. The average weight of all tablets and percentage 
deviation from the mean for each tablet were determined.  
 
 The hardness of formulated tablets was assessed using a hardness tester (PTB 301, 
Pharma Test AG, Hainburg, Germany) and the mean hardness of three tablets was determined. 
The friability was determined on ten tablets using a friability tester (PTF II, Pharma Test AG, 
Hainburg, Germany) and the percentage loss in weight was calculated.  
 
For drug content uniformity test, ten tablets were crushed individually and powder 
equivalent to 25 mg of clozapine was dissolved in 25 mL of methanol. The solution was then 
passed through a 0.45 µm nylon filter and analyzed using UV spectrophotometer (WPA, 
Biochrom Ltd., Cambridge, England) at 290 nm after sufficient dilution with pH 6.4 
phosphate buffer.  
 
One of the most important characteristics of the ODT is its disintegration time in the 
oral cavity; however, a suitable method to access the disintegration properties described in the 
Pharmacopoeias (US, British, Japan and India) has not been developed. At present, the 
disintegration time of ODTs is measured utilizing the conventional tests (for tablets) that were 
described in the Pharmacopoeias. However, it is difficult to assess the disintegration rate for 
the ODT with these tests due to its rapid disintegration rate even in a small amount of water. 
Further, the conventional tests employ a volume of 900 mL of test solution compared to the 
volume of saliva in humans, which is less than 6 mL. Thus, the disintegration rate obtained 
from the conventional disintegration tests appears not to be reflective of the disintegration rate 
in the human mouth (Bi, Sunada et al. 1996). To overcome this problem, several new methods 
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have been proposed such as; disintegration test with charge coupled device (CCD) camera, 
pressurized disintegrating test apparatus (DTA), magnetic signaled DTA, texture analyzer, 
sinker type DTA, shaker type DTA, test tube analysis, wire basket type DTA, etc. (Sharma, 
Hardenia et al. 2009). Among them, the wire basket DTA is considered as a suitable method to 
access the disintegration properties of ODTs.  
 
Briefly, the apparatus (Figure 3.1) consisting of a glass beaker of 1000 mL capacity 
with the wire basket is positioned in the beaker with the help of a support in a way that when 
the beaker is contained 900 mL of disintegrating medium the basket has only 6 mL of it. A 
magnetic bead is placed at the bottom of the beaker maintaining at 37 ± 2
 
0
C. Disintegration 
time is determined at 25 and 50 rpm (Khan, Kataria et al. 2007).  
 
During this study we made an attempt to develop a more suitable apparatus (Figure 
3.2) for the disintegration test. A glass beaker of 10 mL capacity contained 6 mL of pH 6.4 
phosphate buffer as a disintegration medium was placed on the magnetic stirrer. A very small 
magnetic bead was placed at the bottom of a beaker and temperature was maintained at                       
37 ± 2 
0
C. Disintegration time was determined at 50 rpm. The disintegration test was carried 
out on six tablets. 
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                        Figure 3.1 Wire basket type disintegration test apparatus 
 
 
 
          Glass beaker (10 mL) 
                    Wire plaque 
                      6 mL of pH 6.4 phosphate buffer (37 ± 2 0C) 
      Tablet                Magnetic bead  
  
       Magnetic stirrer 
    
 
 
                        Figure 3.2 Modified disintegration test apparatus 
 
rpm Temperature 
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Wetting time was determined by placing five circular tissue papers in a petri dish of 10 
cm diameter (Gohel, Patel et al. 2004). 10 mL of water containing water-soluble blue dye 
(metylene blue) (0.1% w/w) was added to the petri dish. The dye solution was used to identify 
complete wetting of the tablet surface. A tablet was carefully placed on the surface of tissue 
paper in the petri dish at room temperature. The time required for water to reach the upper 
surface of the tablet was noted as the wetting time. These measurements were carried out in 
replicates of three. 
  
The weight of the tablet prior to placement in the petri dish was noted (Wb). The 
wetted tablet was removed and reweighed (Wa). Water absorption ratio (R) was then 
determined according to the following equation.  
 
             Wa – Wb  
 R = 100 X  ------------------- 
        Wb 
 
 Wa: Weight of tablet after water absorption 
 Wb: Weight of tablet before water absorption 
 
3.3.2.4     In vitro dissolution study  
 The USP apparatus II (paddle method) (DTB 678 equipment with thermostatic bath 
and circulation pump VTC-100, Logan Instruments Corporation, New Jersey, USA) was used 
for all the in vitro dissolution studies. In this method, phosphate buffer having the pH of 6.4 
was used as dissolution medium. Phosphate buffer of pH 6.4 was selected as the dissolution 
medium to simulate the pH value of the saliva.  The rate of stirring was 100 rpm. The dosage 
forms were placed in 400 mL of the phosphate buffer maintained at 37 ± 0.5 ⁰C. At 
appropriate intervals (5, 10, 20, 30 and 45 min) 5 mL of the samples were taken. The 
dissolution media was then replaced by 5 mL of fresh dissolution fluid to maintain a constant 
volume. After proper dilution, the samples were analyzed at 290 nm spectrophotometrically 
103 
 
(WPA, Biochrom Ltd., Cambridge, England). The mean of three determinations was used to 
calculate the drug release from each of the formulations. 
 
3.3.2.5     Stability study  
 The effect of aging on the disintegration time and dissolution rate of OD-LSTs was 
determined by storing the tablets at 22 
0
C for up to 6 months. After that, the samples were 
tested for their dissolution profiles and disintegration times at the conditions that have been 
used with freshly prepared tablets. The results were compared with the freshly tested tablets.  
 
3.4  Results and discussion 
3.4.1  Weight variation, hardness, friability, content uniformity, 
disintegration time, wetting time and water absorption capacity tests  
The results of weight variation, hardness, friability, drug content, disintegration time, 
wetting time and water absorption capacity tests are represented in Table 3.2. Average weight 
of OD-LST was 299 ± 2 mg. Average hardness of OD-LST was 45 ± 3 N and the tablets 
possessed acceptable hardness. All the clozapine OD-LSTs had acceptable friability as none of 
the tablets had percentage loss in tablet’s weights that exceed 1%, also no tablet was cracked, 
split or broken. Average percentage drug content was 99 ± 3 % indicating the compliance with 
the pharmacopoeial limits (90-110%).  
 
The most important parameter that needs to be evaluated in the development of ODTs 
is the disintegration time. As per recent US FDA guideline on ODT, disintegration time of 
ODT should have an in vitro disintegration time of approximate 30 s or less (US FDA CDER 
2008), when based on USP disintegration test method or alternative. In the present study, all 
the tablets disintegrated in less than 30 s fulfilling the official requirements for ODTs. The 
OD-LST of clozapine disintegrated within 20 s. CP quickly wicks saliva into the tablet and 
provides rapid disintegration in the mouth (Mohanachandran, Sindhumol et al. 2011). The 
rapid disintegration of OD-LST could be explained by its rapid wetting (wetting time 8 s) and 
its high water absorption capacity (128%). The wetting time is important step for 
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disintegration process to take place (Shankarrao, Mahadeo et al. 2010). The OD-LST showed 
quick wetting, this may be due to ability of swelling and also capacity of absorption of water.  
 
Table 3.2 Physical characterization of clozapine orally  
disintegrating liquisolid tablets  
Test OD-LST 
Weight variation (mg) 299 ± 2 
Hardness (N) 45 ± 3 
Friability (%) 0.22 
Drug content (%) 99 ± 3 
Disintegration time (s) 20 ± 1 
Wetting time (s) 8 
Water absorption (%) 128 ± 2 
 
 
3.4.2     In vitro dissolution study  
The dissolution profiles of clozapine OD-LSTs and DC-ODTs in pH 6.4 phosphate 
buffer are shown in Figure 3.2. It was obvious that drug release from OD-LSTs was much 
faster than that from the regular ODTs. Within 45 min only 68.8% of clozapine was released 
from DC-ODTs as compared to the OD-LSTs with 99.8% drug release.  
 
The enhanced dissolution rates of OD-LST compared to DC-ODT may be attributed to 
the fact that, the drug is already in solution in PG, while at the same time, it is carried by the 
powder particles (MCC, mannitol and CSD). When the drug within the LS system is 
completely dissolved in the liquid vehicle, it is located in the powder substrate still in a 
solubilized state. Therefore they show improved release rates. 
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Figure 3.3 Dissolution profiles of clozapine from orally disintegrating liquisolid tablets  
and directly compressed orally disintegrating tablets (means ± SD; n=3) 
 
3.4.3     Stability study  
 The effect of aging on the disintegration time and dissolution rate of OD-LSTs was 
determined by storing the tablets at 22 
0
C for up to 6 months. The dissolution rate and 
disintegration time were measured for the OD-LSTs at the end of 3 and 6 months. The results 
showed that storage at 22 
0
C neither had an effect on the disintegration time (Table 3.3) nor on 
the release profiles (Figure 3.4) of OD-LSTs. These results indicate that in the case of 
clozapine the OD-LS technology is a promising technique to enhance the release rate without 
having any stability issues.  
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Table 3.3 Disintegration time results of clozapine orally disintegrating liquisolid  
tablets (fresh and aged) 
LS system Disintegration time (s) 
(fresh) 
Disintegration time (s) 
(aged, 3 months) 
Disintegration time (s) 
(aged, 6 months) 
 
OD-LST 20 ± 1 19 ± 1 20 ± 2 
 
 
 
 
 
Figure 3.4 Dissolution profiles of clozapine from orally  
disintegrating liquisolid tablets (fresh and aged) (means ± SD; n=3) 
 
3.5 Conclusion 
LS technique has been used successfully to produce an ODT dosage form of clozapine 
with enhanced dissolution rate. This study demonstrated that formulation of clozapine as   
OD-LST is feasible for enhancing the in vitro dissolution of the drug so it would be possible to 
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hasten the absorption of clozapine and avoids its hepatic first pass metabolism through the 
partial absorption from buccal mucosa and esophagus. The physicochemical properties and 
stability of the prepared LS tablets were satisfactory.  
 
It was concluded that the ODTs of clozapine can be successfully prepared using LS 
technology in order to improve disintegration and dissolution rate of clozapine in oral cavity.   
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Chapter four 
 
4 Conclusion 
LS technique has been used successfully to produce a tablet dosage form of clozapine 
with faster dissolution rate than the regular tablet. Various trials were characterized based the 
blend and tablet parameters which showed the LS formulation containing MCC, CSD and 
SSG with clozapine dissolved in PG as a robust formula with required parameters. It showed 
significant increase in dissolution as compared DCT. It was found that there is a relationship 
between the carrier to coating material ratio (R value) and the in vitro release of clozapine 
from LS tablets. The R value is an important parameter which is the ratio between the weights 
of the carrier and the coating material that may be optimized. An increase in the R value 
results in an enhanced release rate, if MCC and colloidal silica are used as carrier and coating 
materials, respectively. LS compacts with high R values contain high amounts of MCC, low 
quantities of CSD and low liquid to powder ratios. This is associated with enhanced wicking, 
disintegration and thus, enhanced drug release. In contrast, if high amounts of colloidal silica 
are used, which means that the R value is low, the LS compact is overloaded with liquid 
formulation due to a high Lf. In such cases, even though drug diffusion out of the primary 
particles may be rapid, oversaturation might occur resulting in local precipitation or 
recrystallization of the drug and thus decreased release rates (Javadzadeh et al., 2007).  
 
This study showed that the liquid load factor (Lf) has an effect on the flow properties 
of LS powder blends but had no significant effect on the drug release from LS tablets. It was 
observed that aging had no significant effect on the hardness and dissolution profile of 
clozapine LS compacts. In conclusion, this study showed that LS technique could be a 
promising strategy in improving dissolution of poorly water soluble drugs such as clozapine 
and formulating immediate release dosage forms.   
 
In this study OD-LSTs of clozapine were prepared and in vitro evaluated. The 
optimized OD-LST formulation of clozapine showed a significant increase in dissolution rate 
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compared to the regular ODTs. This study demonstrated that formulation of clozapine as              
OD-LST is feasible for enhancing the in vitro dissolution of the drug so it would be possible to 
hasten the absorption of clozapine and avoids its hepatic first pass metabolism through the 
partial absorption from buccal mucosa and esophagus. It was observed that aging had no 
significant effect on the disintegration time and dissolution profile of clozapine OD-LSTs. It  
was concluded that the ODTs can be successfully prepared using LS technology and adding 
superdisintegrants to the formulation in order to improve disintegration and dissolution rate of 
poorly water soluble drugs such as clozapine.  
 
